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Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a 
potentially useful anticancer agent with exquisite selectivity for cancer cells.  
Unfortunately, many cancers exhibit or acquire resistance to TRAIL.  We report 
herein that TRAIL activates a TGF-ß-activated kinase 1→mitogen-activated 
protein kinase (MAPK) kinase 3 (MKK3)/MKK6→p38 pathway in prostate 
cancer cells that transcriptionally upregulates expression of the antiapoptotic BCL-
2 family member MCL-1.  TRAIL alone triggered robust formation of the “death-
inducing signaling complex”, activation of the initiator caspase-8, and truncation 
of the BH3-only protein BID (tBID).  Nevertheless, simultaneous disruption of the 
p38 MAPK pathway was required to suppress MCL-1 expression, thereby 
allowing tBID to activate the proapoptotic BCL-2 family member BAK and 
stimulate mitochondrial outer membrane permeabilization (MOMP). Release of 
the inhibitor-of-apoptosis antagonist, Smac/DIABLO, from the intermembrane 
 vi 
space was sufficient to promote TRAIL-induced apoptosis, whereas release of 
cytochrome c and apoptosome function were dispensable. Even following MOMP, 
however, mitochondrial-generated reactive oxygen species activated a secondary 
signaling pathway, involving c-Jun N-terminal kinases, that likewise upregulated 
MCL-1 expression and partially rescued cells from death.  Thus, stress kinases 
activated at distinct steps in the extrinsic pathway mediate TRAIL resistance 
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Chapter 1. Introduction 
 
1.1  Apoptosis 
 Apoptosis is a programmed form of cell death that plays an important role 
during development and helps maintain tissue homeostasis by ridding the body of 
unwanted, damaged, or infected cells (Kerr et al., 1972). In multicellular 
organisms, the total number of cells is a balance between the cell-generating 
effects of mitosis and cell death that is induced through apoptosis. Therefore, a 
disruption of this delicate balance is associated with many diseases and disorders 
from cancer to neurodegeneration (Fadeel et al., 1999b).  
Several types of cell death have been described including, apoptosis, 
autophagy, and necrosis (Kroemer et al., 2005). Cells undergoing apoptosis show 
typical, well-defined morphological changes, including plasma membrane 
blebbing, chromatin condensation with margination of chromatin to the nuclear 
membrane, karyorhexis (nuclear fragmentation), cytoskeletal collapse, and 
ultimately intact membrane-wrapped “apoptotic bodies” that are engulfed by 
adjacent phagocytes (Kerr et al., 1972). Apoptosis has been characterized by 
several biochemical criteria, including caspase activation, phosphatidylserine (PS) 
exposure on the outer leaflet of the plasma membrane (Fadok et al., 1992), 
changes in mitochondrial membrane permeability (Kroemer and Reed, 2000), 
release of proteins from the mitochondrial intermembrane space (Van Loo et al., 
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2002), and caspase-dependent activation and nuclear translocation of DNase that 
induces internucleosomal DNA cleavage (Enari et al., 1998). Identification of 
these morphological and biochemical markers of apoptosis makes it possible to 
distinguish it from other forms of cell death. Cells undergoing autophagy are 
characterized by the presence of double membrane autophagic vacuoles. 
Autophagy is primarily a survival mechanism that is activated in cells subjected to 
nutrient or obligate growth factor deprivation. When cellular stress continues, cell 
death may continue by autophagy alone, or more often becomes associated with 
features of apoptotic or necrotic cell death. Specific biochemical markers have 
been determined for autophagy, such as conjugation of light chain 3 (LC3) to the 
phosphatidylethanolamine (PE) on autophagosomal membranes, which can be 
detected as a band shift by western blotting (Kabeya et al., 2000). In contrast, 
necrosis is characterized by rapid cytoplasmic swelling. It culminates in rupture of 
the plasma membrane and breakdown of organelles (Majno and Joris, 1995). 
Necrosis has long been described as a consequence of extreme physicochemical 
stress such as heat, osmotic shock, mechanical stress, freeze-thawing, or exposure 
to reactive oxygen species (ROS). Under these conditions, necrotic cells undergo 
cytosolic and mitochondrial swelling, resulting in loss of membrane integrity and 
cell lysis, and this death occurs quickly due to the direct effect of the stress on the 
cell. Therefore, this cell death process has been described as accidental and 
uncontrolled.  
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 As already noted, apoptosis is implicated in many diseases because it is 
critical for various aspects of development, including the removal of structures 
with transient functions, tissue sculpting, and morphogenesis. Thus, proper 
regulation of apoptosis is important to maintain the health of living organisms and 
deregulation can contribute to the pathogenesis of various diseases (Thompson, 
1995). Apoptosis has been shown to play an important role in cancer, human 
immunodeficiency virus-1 (HIV-1) infection, autoimmune diseases, and 
neurodegenerative disorders such as Alzheimer’s, Huntington’s, and Parkinson’s 
disease. In each case, apoptosis is either abnormally inhibited (as in cancer) or is 
induced as in the case of HIV-1 infection. Among the diseases associated with 
inhibition of apoptosis, cancer is the second leading cause of mortality in the 
world. The successful treatment of cancer therefore is one of the greatest 
challenges of modern medicine. Although many scientists have made 
considerable strides in understanding how tumor cells survive and die over the 
past 20 years, and conventional treatments such as radiotherapy and 
chemotherapy continue to benefit patients with cancer, significant advances in 
survival are not expected with these therapies alone. Thankfully, by understanding 
the molecular mechanisms of apoptosis more rational approaches to cancer 
treatment are in development. One promising approach is the design of TRAIL 
receptor agonist and considerable progress has been made in this area. More 
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information about TRAIL and its roles in apoptosis will be covered in section 
1.2.1.2. 
 
1.2 Apoptotic pathways 
The execution of apoptosis is made possible by a group of cysteinyl 
aspartate-specific proteases known as caspases.  Caspases are synthesized in the 
cytosol as 30-50 kD single-chain zymogens, and in most cases are activated 
following intramolecular cleavage at specific aspartate residues (Cohen, 1997).  
Two well-characterized signaling pathways that activate caspase cascades, 
leading to activation of apoptosis, are the death receptor (extrinsic) and the 
mitochondrial (intrinsic) pathways. These two pathways are initiated in response 
to different stimuli, which ultimately converge to activate the effector caspases 
leading to cellular demise in a similar fashion.  
Diverse stressors activate the intrinsic pathway, which results in release of 
cytochrome c from the mitochondrial intermembrane space into the cytoplasm (Li 
et al., 1997), followed by dATP/ATP-dependent formation of a multimeric 
apoptotic protease-activating factor-1 (Apaf-1) apoptosome complex (Acehan et 
al., 2002; Cain et al., 1999) . This complex recruits and activates caspase-9 and 
other effector caspases, that can further cleave numerous substrates like ICAD, 
PARP, lamins, cytokeratins, etc. to induce apoptosis (Bratton and Cohen, 2001; 
Bratton et al., 2000; Bratton et al., 2001). In addition to cytochrome c, other 
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apoptosis-promoting factors are also released from several sub-cellular 
compartments to induce apoptosis. More information about the intrinsic pathway 
will be covered in section 1.2.1. 
Similarly, the extrinsic pathway is generally activated in response to 
external signals in the form of death ligands (e.g TNF, TRAIL, and CD95L).  
These are potent cytokines, produced by many cell types, including macrophages, 
monocytes, lymphocytes, keratinocytes, and fibroblasts in response to 
inflammation, infection, injury, and other challenges.  When these ligands interact 
with their corresponding receptors, a membrane-bound, caspase activating 
multiprotein assembly called the ‘death-inducing signaling complex’ (DISC) is 
formed (Scaffidi et al., 1999). Some components in the DISC facilitate the 
binding and activation of procaspase-8 and as a result, apoptosis ensues.  
However, the DISC also induces the expression of inflammatory antiapoptotic 
genes that counteract the cell death response in a cell-type and stimulus-specific 
manner. 
There are several mechanisms through which the assembly of the DISC or 
the apoptosome complex can be prevented, but once they are formed and begin 
activating caspases, the inhibitor of apoptosis (IAP) protein become the main 
inhibitor of cell death.  In normal cells that have not received an apoptotic 
stimulus, most caspases remain inactive.  Even if some caspases are aberrantly 
activated, their proteolytic activities or presence in the cell can be fully regulated 
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by the evolutionarily-conserved IAPs (Choi et al., 2009; Deveraux et al., 1998; 
Eckelman and Salvesen, 2006). Several distinct mammalian IAPs, including X-
linked IAP (XIAP), cellular IAP 1 (cIAP1), cIAP2, neuronal apoptosis inhibitory 
protein (NAIP), survivin, ML-IAP/Livin, BRUCE/Apollon, and IAP-like protein 
2 (ILP2) have been identified, and they all exhibit antiapoptotic activity in 
different contexts, though only XAIP directly inhibits caspase activity. Each of 
the IAPs contains one or more tandem repeats of ~70 amino acids, forming the 
Baculoviral IAP Repeat domains, which in the case of XAIP, directly interact 
with and inhibit the enzymatic activity of certain mature caspases, namely 
caspase-3, -7, and -9 through its linker-BIR2 and BIR3 domains (Sun et al., 2000; 
Takahashi et al., 1998).  In some cases, IAPs also contain a caspase-recruitment 
domain (CARD), a UBA domain, and/or a carboxy-terminal RING zinc-finger 
domain, conferring an ubiquitin E3 ligase activity (Deveraux and Reed, 1999).  
Apoptotic signals require that the IAP-mediated inhibitory effect on 
caspases be removed; a process performed by a mitochondrial protein named 
Smac (second mitochondria-derived activator of caspases) or DIABLO (direct 
IAP binding protein with low pI) (Du et al., 2000; Verhagen et al., 2000). Upon 
apoptotic stimuli, Smac/DIABLO is released from the intermembrane space of 
mitochondria into the cytosol, together with cytochrome c. Whereas cytochrome c 
directly activates Apaf-1 to facilitate  formation of the apoptosome, 
Smac/DIABLO interacts with multiple IAPs and relieves their inhibitory effects 
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on both the initiator caspase-9 and the effector caspase-3 and -7 (Shi, 2002).  In 
addition to Smac, other pro-apoptotic factors like Omi/ HtrA2 also interact with 
IAPs to induce apoptosis (Martins et al., 2002; Suzuki et al., 2001; Verhagen et al., 
2002). 
 
1.2.1  The extrinsic death receptor pathway 
 The extrinsic pathway of apoptosis is brought about, when death ligands 
bind and activate their corresponding death receptors to recruit and activate 
caspases.  Most of these death ligands belong to the TNF family and are type II 
transmembrane proteins (Smith et al., 1994). Specific metalloproteases of the 
ADAM family, however, can cleave these ligands to generate soluble forms 
(Idriss and Naismith, 2000).  
 
1.2.1.1  TNF and TNFR1 signaling 
Tumor necrosis factor (TNF), a major mediator of apoptosis as well as 
inflammation and immunity, has been implicated in the pathogenesis of a wide 
spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, 
multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases (Chen 
and Goeddel, 2002). TNF signals through two distinct cell surface receptors – 
TNF receptor1 (TNFR1) and TNFR2. Most cell types constitutively express 
TNFR1 while TNFR2 expression is highly restricted to cells of the immune 
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system (Smith et al., 1994; Tartaglia and Goeddel, 1992). The interaction of the 
trimeric TNF ligand with its receptors results in formation of the DISC at the cell 
membrane, (Chinnaiyan et al., 1996; Hsu et al., 1996a; Hsu et al., 1996b; Hsu et 
al., 1995) which triggers a series of intracellular events that ultimately result in 
the activation of two major transcription factors, nuclear factor κB (NF-κB) and 
AP-1 (Brenner et al., 1989; Osborn et al., 1989). These transcription factors are 
responsible for the inducible expression of genes important for diverse biological 
processes, including cell growth and death, development, oncogenesis, immunity, 
inflammation, and other stress responses (Chen and Goeddel, 2002). TNF can 
simultaneously activate another signaling pathway with a strikingly different 
outcome. This involves the recruitment of Fas-associated death domain (FADD) 
and caspase-8 to the TNFR1 complex, where caspase-8 becomes activated, 
presumably by dimerization and self-cleavage, and initiates a protease cascade 
that leads to apoptosis (Wallach et al., 1999) (Figure 1.1). 
Membrane-bound TNF (mTNF) is present as a trimer and is cleaved 
specifically by TNFα-converting enzyme (TACE) to generate its soluble form 
(sTNF) (Black et al., 1997; Tang et al., 1996). Moreover, mTNF binds and 
activates TNFR1 and TNFR2, while sTNF interacts with both receptors but 
reportedly activates only TNFR1 (Grell et al., 1998). The extracellular domains of 
TNF receptors have cysteine-rich domains (CRD), which are pseudorepeats 
containing six cysteine residues forming three disulfide linkages (Bodmer et al., 
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2002). The cytoplasmic tail of the receptor contains a stretch of 60-70 amino acids 
making up the death domain (DD) (Ashkenazi and Dixit, 1998), which plays the 
primary role in forming the DISC complex, mediated through protein-protein 
interactions. The first protein to interact with the DD of TNFR1 is TNFR1-
associated death domain protein (TRADD), which acts as a platform to bind three 
other proteins including TNF receptor associated factor2 (TRAF2), receptor-
interacting protein 1 (RIP1) and FADD (Chinnaiyan et al., 1996; Hsu et al., 
1996a; Hsu et al., 1996b). The TRADD-TRAF2-RIP complex is known to be 
essential for NF-κB activation, whereas the interaction between TRADD and 
FADD allows the recruitment and activation of caspase-8 and facilitates the 
apoptotic wing of the response (Hsu et al., 1995). 
TRAF2 like other TRAF proteins has a C-terminal TRAF domain and an 
N-terminal RING Zn finger domain (Takeuchi et al., 1996). The N-terminus is 
important for c-jun N-terminal kinase (JNK) and p38 MAPK activation, via 
interactions with several MAPK kinase kinases (MKKKs) like transforming 
growth factor-ß-activated protein 1 (TAK1) and apoptosis signal-regulating 
kinase 1 (ASK1) (Carpentier et al., 1998; Ichijo et al., 1997b; Rothe et al., 1995b), 
and the C-terminal domain, called TRAF domain, is further subdivided into a 
more divergent N-proximal (TRAF-N) and a highly conserved C-proximal 
(TRAF-C) subdomain. The TRAF domain is responsible for trimerization and 
interaction with adapter molecules in TNFR1 signaling. The TRAF-N domain 
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contains a coiled-coil domain that forms a single alpha-helix, and the TRAF-C 
domain forms a novel eight-stranded anti-parallel beta-sandwich (Park et al., 
1999). Both domains are necessary to form a trimer in the shape of a mushroom, 
with the TRAF-C domain as the cap, and the TRAF-N domain as the stalk 
(McWhirter et al., 1999). Furthermore, interaction of TRAF2 with TRADD 
requires a C-terminus of the TRAF-C domain, whereas interaction with RIP1 
occurs via an N-terminus of the TRAF-C domain (Takeuchi et al., 1996). In 
addition to activating JNK and p38 MAPK, TRAF2 is critical for recruiting IkB 
kinase (IKK) complex to TNFR1 and activating the IKK complex, composed of 
three subunits including IKKα, IKKß, and IKKγ (NEMO) (Devin et al., 2000). 
The IKK complex then activates NF-κB by promoting phosphorylation-dependent 
degradation of inhibitor of NF-κB (IkB). Although TRAF2-/- fibroblasts exhibit a 
total loss of TNF-induced JNK activation, there is just a decrease in NF-κB 
activation (Yeh et al., 1997), and TNF-induced NF-κB  activation is not 
significantly inhibited in TRAF5-/- fibroblasts (Nakano et al., 1999). However, 
TRAF2-/- and TRAF5-/- fibroblasts show a significant inhibition of NF-κB  
activation (Tada et al., 2001), suggesting that TRAF2 and TRAF5 play a 
redundant role in the TNF-induced NF-κB  activation. Cellular IAPs (cIAPs) are 
recruited in the TNFR1 DISC assembly through interaction with TRAF2 via their 
BIR domain (Rothe et al., 1995a). Although cIAPs might appear to participate in 
NF-κB signaling, the precise mechanism underlying this activity is not known in 
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the TNFR1 signaling. However, recent study indicates that TNFα-induced NF-κB 
activation is significantly inhibited in the absence of both cIAP1 and cIAP2 
(Varfolomeev et al., 2008). In addition to modulating TNFα-induced NF-κB 
activation, cIAPs have been shown to suppress caspase-8 activation in TNFα-
induced apoptosis (Wang et al., 1998).  
TRADD in addition to binding with TRAF2 also binds with RIP1 that has 
been found to be a key effector in NF-κB activation by TNFR1 (Hsu et al., 1996a).  
Furthermore, a C-terminal caspase-8-dependent cleavage of RIP1 blocks NF-κB 
activation, and promotes cell death (Lin et al., 1999). In addition, RIP1 lacking an 
intermediate domain drastically reduced TNF-mediated p38 activation (Yuasa et 
al., 1998).  In direct contrast to what was observed with TRAF2 -/- cells, cells 
devoid of RIP1 do not mount any NF-κB response, but still activate JNK (Kelliher 
et al., 1998). The NF-κB activating property of RIP1 is independent of its kinase 
activity (Ting et al., 1996) and for this reason, RIP1 is considered a critical 
adaptor protein, helping in the recruitment of IKKs to the activated TNFR1 
complex via interaction with NEMO (NF-κB essential modulator or IKKγ) 
(Zhang et al., 2000). Degradation of RIP1 following ubiquitination is achieved by 
A20, another factor recruited to the DISC that serves as a check point for RIP1-
mediated NF-κB activity and apoptosis (Lee et al., 2000; Wertz et al., 2004).  
The recruitment of FADD and caspase-8 to the TNFR1 DISC has been 




Figure 1.1  TNFR1 signaling  
 
The initial step in TNFR1 signaling - the binding of TNF to TNF-R1 results in the 
recruitment of TRADD, which recruits additional adaptor proteins, like RIP and 
TRAF2 to the cytoplasmic death domains of TNFR1. TRAF2 recruits cIAPs1 and 
2 and other TRAFs, thus forming complex I that can activate the IKK/ NF-κB and 
other MAPK pathways. Subsequently, this complex undergoes biochemical 
modifications and dissociates from TNFR1, and interacts with FADD and caspase 
8, forming the DISC (complex II) in the cytosol. Binding of caspase-8 causes its 
activation and results in apoptosis.   
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TNFR1 receptor complex isolated from cells, following stimulation (Harper et al., 
2003). It has been shown that upon stimulation with TNF, the trimeric receptor 
assembles all its cytoplasmic components in lipid rafts.  This initial complex, 
called complex I, containing TNFR1, TRADD, TRAF2, RIP, and possibly other 
proteins, triggers the activation of NF-κB (Micheau and Tschopp, 2003).  
However, formation of complex I is transient and a large portion of the 
cytoplasmic protein components that constitute the DISC dissociate within an 
hour of stimulation. After dissociation, the DD of TRADD is available for 
interacting with the DD of FADD and as a result, caspase-8 gets recruited and 
activated (complex II) in the cytosol or in the endocytic vesicles (Micheau and 
Tschopp, 2003; Schneider-Brachert et al., 2004) (Figure 1.1). Afterwards, 
activated caspase-8 can either activate other downstream effector caspases, like 
caspases-3 and -7 (as in type I cells), or if activated only in very small quantities 
owing to inefficient DISC formation, caspase-8 can truncate BID, to form tBID, 
leading to release of cytochrome c which in turn activates the intrinsic pathway 
(as in type II cells) (Kuwana et al., 1998; Luo et al., 1998). Activation of caspase- 
8 can be inhibited through recruitment of FLIP to the DISC, which competes with 
procaspase-8 for binding to FADD, thereby blocking cell death (Irmler et al., 
1997; Micheau et al., 2001).  
 
1.2.1.2  TRAIL and TRAIL receptor signaling 
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 TRAIL was discovered independently by two groups as a proapoptotic 
ligand that belongs to the TNF gene family (Pitti et al., 1996; Wiley et al., 1995). 
This ligand was called TRAIL or Apo-2L, respectively, because of its high 
homology to other members of the TNF family including Fas/Apo-1L (Pitti et al., 
1996; Wiley et al., 1995). The TRAIL gene is located on chromosome 3 and spans 
approximately 20 kb, which is composed of five exons and four introns. TRAIL is 
a type II transmembrane protein and consists of 281 and 291 amino acids in the 
human and murine, respectively, which share 65 % identity. TRAIL has a short 
cytoplasmic N-terminus that is not conserved across the other TNF family 
members, whereas its long C-terminal extracellular domain shows significant 
conservation. The percent identity to the more related members of the TNF family, 
FasL and TNFα, is 28 and 22%, respectively (Wiley et al., 1995). TRAIL is 
mostly expressed on the surface of natural-killer (NK) cells and cytotoxic T cells 
and seems to play a role in the killing of virus-infected or malignant cells by these 
immune effector cells (Smyth et al., 2003). TRAIL is different in structure from 
the other prototypical ligands such as TNFα and FasL in structure. After cleavage 
of the extracellular C-terminal portion of TRAIL from the cell surface, TRAIL is 
released by the cells as a soluble form (Mariani et al., 1997). The soluble form of 
TRAIL comprising amino acids 114 to 281 is biologically active (Marsters et al., 
1996; Pitti et al., 1996). Similar to the other TNF family members, TRAIL is a 
homotrimeric molecule. However, TRAIL is the only protein of the TNF family 
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that contains an essential cysteine residue, cys230, which allows the interaction 
among three molecules of TRAIL. The central zinc ion bound by the cysteines in 
the trimic ligand is essential for trimerization, solubility, stability, and biological 
activity (Bodmer et al., 2000b; Hymowitz et al., 1999; Mongkolsapaya et al., 
1999).   
  
1.2.1.2.1  TRAIL receptors 
 Five human TRAIL receptors have been identified. The first receptor, 
TRAIL-R1 (DR4/APO-2), was indentified in 1997 (Pan et al., 1997b). Another 
receptor, TRAIL-R2 (DR5/KILLER/TRICK2) was described in the same year 
(Pan et al., 1997a; Screaton et al., 1997; Sheridan et al., 1997; Walczak et al., 
1997; Wu et al., 1997). These receptors can signal for cell death and share a 
sequence homology of 58 percent, but whether they have distinct functions 
remains unclear. The cytoplasmic domains of these receptors share significant 
homology with the DDs found in FasL and TNFR1. The cysteine-rich domains in 
the extracellular part are another common feature of these receptors. In addition to 
the apoptosis-inducing receptors, TRAIL-R1 and R2, two receptors have been 
found which fail to transmit the apoptotic signal, namely TRAIL-R3 
(DCR1/TRID) (Degli-Esposti et al., 1997b; Pan et al., 1997b) and TRAIL-R4 
(DCR2) (Degli-Esposti et al., 1997a), also called decoy receptors. Both receptors 
share high homology with the extracellular domain of the apoptosis-inducing 
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receptors. However, TRAIL-R3 lacks the complete intracellular DD that is 
essential for signaling apoptosis, and TRAIL-R4 has a cytosolic portion which 
contains only a truncated DD. Thus, neither receptor is able to induce apoptosis. 
Instead of induing apoptosis, they inhibit TRAIL-R1 and TRAIL-R2-mediated 
apoptosis. Overexpression experiments have shown that the decoy receptors 
compete with TRAIL-R1 and/or TRAIL-R2 for binding to TRAIL (Degli-Esposti 
et al., 1997a; Degli-Esposti et al., 1997b). Finally, osteoprotegerin (OPG) has 
been reported as a fifth receptor for TRAIL (Emery et al., 1998). OPG acts mainly 
as a regulator in the development and activation of osteoclasts during bone 
remodeling. However, this is not due to the interaction of OPG with TRAIL. OPG 
has also been proposed to function as a decoy receptor by binding TRAIL, and 
thus blocking apoptosis (Pritzker et al., 2004). Thus, the role of OPG as a TRAIL 
receptor is less well characterized compared with the other receptors. 
  
1.2.1.2.2  Physiological roles of TRAIL 
 TRAIL is a cytokine that is expressed by effector lymphocytes and plays a 
role in shaping and regulating the immune system. The expression level of 
TRAIL is extremely low in freshly isolated lymphocytes (Takeda et al., 2001a). 
Furthermore, only a small set of murine NK cells express detectable TRAIL, and 
it appears most likely that the expression of TRAIL on liver NK cells is regulated 
by secretion of interferon (IFN)-γ from NK cells (Takeda et al., 2001b). 
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Stimulation of dendritic cells with IFN-ß has been shown to increase the 
expression of TRAIL by enhancing the cytotoxicity of dendritic cells on tumor 
cells (Liu et al., 2001b). Thus, TRAIL plays an important role in regulating the 
innate immune response involving NK and dendritic cells. TRAIL also 
contributes to the host immunosurveillance against metastasis, an effect 
apparently restricted to liver NK cells. Both neutralizing anti-mTRAIL mAB and 
TRAIL knockout mice support a direct role for TRAIL expressing NK cells in the 
suppression of tumor metastasis, (Cretney et al., 2002; Takeda et al., 2001a). In 
addition to the physiological role of TRAIL in tumor immunesurveillance, TRAIL 
is also implicated in regulating autoimmunity. Several studies have reported 
increases in the serum levels of soluble TRAIL in patients with systemic lupus 
erythrmatosus (Lub-de Hooge et al., 2005), and TRAIL may serve as a potential 
marker in determining the sensitivity of multiple sclerosis patients to INF 
treatment (Wandinger et al., 2003). 
  
1.2.1.2.3  TRAIL receptor signaling 
TRAIL-induced apoptotic signaling is reportedly simpler than TNFR1 
signaling, but TRAIL triggers apoptosis through formation of DISC similar to 
TNF. The interaction of TRAIL with its two death receptors, DR4 and DR5, is the 
initial step, which in turn leads to recruitment of FADD through its DD and 
caspase-8 through its N-terminal death effector domain (DED). Formation of the 
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Figure 1.2  TRAIL receptor signaling  
TRAIL induces apoptosis and pro-survival signaling. Activation of TRAIL-R1 
and/or -R2 induces trimerization and formation of a primary DISC complex in 
lipid rafts, leading to apoptosis signaling. DISC-induced caspase-8 activation 
either directly activates the effector caspase-3 and triggers apoptosis or does so 
indirectly via Bid cleavage and activation of the intrinsic pathway. A secondary 
signaling complex is thought to be formed outside lipid raft structures, leading to 
activation of the transcription factor NF-κB and MAPKs and increased expression 
of antiapoptotic proteins.  
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TRAIL DISC promotes the activation of procaspase-8 by inducing dimerization 
within the DISC and this dimerization leads to its catalytic activation. Caspase-10 
is also recruited to FADD through its DEDs and is cleaved with similar kinetics as 
caspase-8 (Kischkel et al., 2001). However, the importance of caspase-10 for the 
DISC is unclear and controversial. Several previous studies have failed to identify 
caspase-10 in the DISC or detect caspase-10 activation by engagement of FasL or 
TRAIL receptors (Bodmer et al., 2000a; Juo et al., 1998; Kischkel et al., 2000; 
Sprick et al., 2000). Once activated, caspase-8 activates the downstream effector 
caspase-3, which dismantles the cells. Like TNFR1 signaling, caspase-8 also 
cleaves Bid and activates the intrinsic pathway (Figure 1.2). Unlike FasL and 
TNF, however, there is currently no evidence to suggest that internalization of the 
TRAIL DISC is required for cell death (Kohlhaas et al., 2007). In addition to 
inducing apoptosis, TRAIL receptor stimulation also leads to activation of various 
signaling pathways, including activation of the IKK complex, MAPKs, and JNKs 
(Devin et al., 2000; Harper et al., 2003; Varfolomeev et al., 2005) (Figure 1.2).  
Although not required for apoptosis, TRAIL receptors reportedly undergo 
internalization and caspase-8-dependent formation of a secondary signaling 
complex (Kohlhaas et al., 2007; Varfolomeev et al., 2005).  This intracellular 
complex contains RIP and TRAF2, which then signal for the activation of IKK 
and the stress kinases, p38 MAPKs and JNKs, through ill-defined mechanisms 
(Varfolomeev et al., 2005).  Robust activation of these pathways also occurs 
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following treatment with TNF, and in particular, activation of the transcription 
factor NF-κB by IKK suppresses TNF-induced apoptosis in most cell types 
through upregulation of various antiapoptotic genes (Kelliher et al., 1998; 
Micheau and Tschopp, 2003; Song et al., 1997; Tobiume et al., 2001; Yuasa et al., 
1998).  By comparison, TRAIL activates these pathways to a lesser extent and 
their importance in regulating TRAIL-induced apoptosis remains unclear 
(Varfolomeev et al., 2005).  
 
1.2.2  The intrinsic mitochondrial pathway  
The intrinsic pathway is activated in response to developmental cues, 
growth factor withdrawal, DNA damage, cytoskeletal damage, oxidative stress, 
lysosomal injury, endoplasmic reticulum (ER) stress, etc. Mitochondria are 
involved in the production of ATP via oxidative phosphorylation, and they 
possess an inner mitochondrial membrane (IMM), which surrounds the matrix, 
and an outer mitochondrial membrane (OMM), which surrounds and separates the 
inter membrane space (IMS) from the cytoplasm (Fadeel et al., 1999a) (Figure 
1.3). The IMM forms cristae and contains molecules, such as cytochrome c, 
which functions as an electron carrier, transferring electrons from complex III to 
complex IV during oxidative phosphorylation. Mitochondria maintains an inner 
membrane potential (∆ψM) by pumping H+ from the matrix into the IMS, and this 
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Figure 1.3  The intrinsic mitochondrial pathway  
 
The intrinsic pathway is regulated by proapoptotic and antiapoptotic BCL-2 
family members. When cells are damaged by death stimuli, BAX and/or BAK 
undergo a conformational change leading to their activation, which in turn results 
in release of several proapoptotic factors into the cytosol, including cytochrome c 
and Smac/DIABLO. Cytochrome c then triggers formation of the apaf-1·caspase-
9 apoptosome, which activates caspase-3. On the other hand, Smac/DIABLO 
antagonizes XIAP, which relieves the inhibition of caspases including caspases-
3,-9, and -7 by XIAP. The figure is modified from Chapter 2. Alterations in cell 
signaling: Apoptosis. Comprehensive Toxicology. (2009). 
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provides the driving force for ATP production. During stress-induced apoptosis, 
the mitochondrial outer membrane is permeabilized, resulting in release of several 
proapoptotic factors into the cytosol, including cytochrome c, apoptosis-inducing 
factor (AIF), endonuclease G, Smac/DIABLO, and Omi/HtrA2 (Du et al., 2000; 
Li et al., 2001; Susin et al., 1999; Suzuki et al., 2001; Verhagen et al., 2000). 
Following MOMP, the released cytochrome c binds to Apaf-1, which consists of 
an N-terminal nucleotide binding domain (NBD), CARD and a series of C-
terminal WD-40 repeats. Apaf-1, upon binding to cytochrome c through its WD-
40 repeats, binds to ATP/dATP and undergoes oligomerization via its NBD into a 
heptameric complex termed the apoptosome (Acehan et al., 2002; Li et al., 1997). 
These interactions expose the CARD domain of Apaf-1, thus making it competent 
to bind the prodomain of caspase-9. Procaspase-9 once recruited to the 
apoptosome is activated and undergoes self-processing in the linker region 
between the large and small subunits (Srinivasula et al., 1998). Active caspase-9 
activates effector caspases-3 and -7, which in turn cleaves more than 500 
intracellular substrates thus leading to apoptosis (Li et al., 1997; Walsh et al., 
2008) (Figure 1.3). 
 The activated caspases are further regulated by a conserved IAP family of 
proteins like XIAP. XIAP consists of three BIR domains (BIR1-3) and a C-
terminal RING domain (Duckett et al., 1996; Uren et al., 1996). The BIR domains 







Figure 1.4  Functional domains of XIAP 
 
XIAP has three BIR domains two of which have distinct functions in inhibiting 
different caspases.  XIAP inhibits caspases-3 and -7 via its BIR2 domain and an 
adjacent linker region, while caspase-9 is inhibited by the BIR3 domain. The 
RING domain on the C-terminus of XIAP has E3 ubiquitin ligase activity. 
Smac/Diablo antagonizes XIAP by displacing the bound caspases through 
interaction with the BIR2 and BIR3 domains of XIAP. The figure is modified 





binds exclusively to processed caspase-9 through a motif located on the N-
terminus of the freshly cleaved small subunit, thereby potently inhibiting its 
activity (Huang et al., 2001; Srinivasula et al., 2001). With respect to the effector 
caspases-3 and -7, the linker region located between the BIR1 and BIR2 domains 
of XIAP plays an important role in binding and inhibiting the caspase activity. 
This linker region binds into the active site of effector caspases-3 and -7, in the 
opposite orientation to a normal substrate, thereby preventing cleavage of the 
linker and access to substrates (Chai et al., 2001; Huang et al., 2001; Riedl et al., 
2001) (Figure 1.4). XIAP inhibition of caspases is reversible and can be displaced 
through binding of IAP antagonists, such as Smac/DIABLO. Smac/DIABLO   
contains 239 amino acids, but its N-terminal 55 residues encode the 
mitochondrial-targeting sequence, which is proteolytically removed upon 
importation into mitochondria. This cleavage results in the exposure of four 
hydrophobic amino acids, Ala-Val-Pro-Ile, at the N-terminus of mature Smac (Du 
et al., 2000; Verhagen et al., 2000). The N-terminal Ala of the IAP binding motif 
(IBM) binds into a hydrophobic pocket in the BIR2 and BIR3 domains of XIAP 
(Liu et al., 2000; Srinivasula et al., 2000). Smac/DIABLO, through its IBM, 
antagonizes XIAP by displacing the bound caspases. The N-terminus of the 
caspase-9 small subunit and the IBM of Smac/DIABLO compete for the 
hydrophobic pocket in the BIR3 domain, decreasing the ability of XIAP to bind 
and inhibit caspase-9 (Wu et al., 2000). Similarly, XIAP inhibition of caspase-3 is 
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also neutralized by the interaction of Smac/DIABLO to the BIR2 domain (Chai et 
al., 2000) (Figure 1.4).  
 
1.3  BCL-2 family members. 
 BCL-2 family members help maintain mitochondrial integrity and regulate 
apoptosis, either by inhibiting or promoting MOMP. There are, at least, twenty 
mammalian Bcl-2 members, and they are divided into antiapoptotic and 
proapoptotic members. The antiapoptotic BCL-2 family members include BCL-2, 
BCL-XL, MCL-1, BCL-W, and A1, which serve as effective barriers to the 
intrinsic pathway and are characterized by the presence of four α-helical BCL-2 
homology (BH) domains (BH1-4), with the exception of MCL-1 (BH1-3) and A1 
(BH1-2). The proapoptotic members are subdivided into two classes: the BH3-
only members (BID, BIM/BOD, BAD, NOXA, PUMA, BBC3, BMF, HRK/DP5, 
BIK/BLK/NBK, and MULE) and the multidomain (BH1-3) members (BAX, 
BAK, and BOK/MTD) (Youle and Strasser, 2008) (Figure 1.5). 
 Two multidomain proapoptotic members, BAX and BAK, are essential for 
MOMP, leading to the completion of apoptosis. In the case of BAX, the induction 
of apoptosis and the associated change in its cellular localization reflects the 
ability to undergo a conformational change from a soluble to an integral 
membrane conformation. BAX is composed of 9 alpha helices separated by rather 




Figure 1.5  Classification of BCL-2 family members 
 
Bcl-2 family members are divided into anti- or proapoptotic family members. 
Antiapoptotic Bcl-2 family members are characterized by the presence of four BH 
domains with the exception of MCL-1 and A1. The proapoptotic BCL-2 family 
members are further subdivided into two subfamilies: the multidomain members, 
which are characterized by the presence of BH1-3 domains, and the BH3-only 
members.  
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are mostly hydrophobic and constitute the core of the protein. The other 7 helices 
have amphipathic properties and keep their hydrophilic residues exposed to the 
exterior. This organization enables the protein to remain soluble in its native 
cytosolic conformation (Suzuki et al., 2000). BAX appears to exist as a monomer 
in the cytosol rather than being bound to any antiapoptotic BCL-2 family 
members (Hsu and Youle, 1998). During apoptosis, a major conformational 
change occurs, wherein several domains, formerly hidden in the native 
conformation, become exposed. Its C-terminal transmembrane domain (helix α9) 
is first exposed, resulting in translocation of BAX to mitochondria. BAX then 
inserts into the OMM and undergoes homooligomerization (Mikhailov et al., 
2003; Nechushtan et al., 1999; Suzuki et al., 2000). The N-terminus of BAX 
(helix α1) is also exposed during its targeting to mitochondria (Cartron et al., 
2003). On the other hand, BAK is normally localized to the OMM, but during 
apoptosis BAK similarly undergoes a conformational change that exposes its N-
terminus and facilitates oligomerization (Griffiths et al., 1999). 
The antiapoptotic BCL-2 family members are critical for regulating 
MOMP by inhibiting the multidomain proapoptotic members, BAX and BAK to 
ensure mitochondrial integrity. BAX is inhibited by BCL-2, BCL-XL, MCL-1, 
and BCL-W, while BAK is inhibited exclusively by MCL-1 and BCL-XL (Youle 
and Strasser, 2008). Similarly, the BH3-only proteins also possess different 
affinities for the antiapoptotic BCL-2 family members. BIM, BID, and PUMA 
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Figure 1.6  Models of BAX/BAK activation by BH3-only proteins 
 
(A) Indirect activation model: BH3-only proteins antagonize BCL-2, BCL-XL, 
and MCL-1, which restrain BAX and BAK. (B) Direct activation model: BH3-
only proteins serve as either direct “activators” of BAX and BAK, or they 
function as “sensitizers” by displacing the activators from antiapoptotic BCL-2 
family members such as BCL-2, BCL-XL, and MCL-1. The figure is modified 
from Chapter 2. Alterations in cell signaling: Apoptosis. Comprehensive 
Toxicology. (2009). 
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bind to all antiapoptotic members. By contrast, BAD and NOXA selectively 
inhibits BCL-2/ BCL-XL/BCL-W and MCL-1/A1, respectively (Figure 1.6). The 
BH3-only proteins activate BAX and BAK through two models known as the 
“indirect activation and direct activation models”. In the indirect activation model, 
BAX and BAK are inhibited by the antiapoptotic BCL-2 family members and the 
BH3-only proteins induce BAX/BAK activation and apoptosis by neutralizing the 
antiapoptotic BCL-2 family members. The hydrophobic binding groove of the 
antiapoptotic BCL-2 family members is occupied by the BH3 domain of the BH3-
only proteins (Chipuk and Green, 2008; Youle and Strasser, 2008) (Figure 1.6). 
By contrast, in the direct activation model, the BH3-only proteins are classified as 
either “activators” or “sensitizers” (Cheng et al., 2001; Letai et al., 2002). 
Activators (tBID, BIM, and PUMA) are proposed to directly interact (via their 
BH3 domains) with BAX or BAK, thereby promoting BAX/BAK activation. 
Indeed, it has been reported that tBID can induce BAX pore formation in large 
unilamellar vesicles (Kuwana et al., 2002). Sensitizer BH3-only proteins, on the 
other hand, lack the ability to interact directly with BAX or BAK, but can bind to 
antiapoptotic BCL-2 family members, thereby displacing the activator BH3-only 
proteins and allowing these BH3 proteins to activate BAX and BAK (Cheng et al., 
2001; Letai et al., 2002) (Figure 1.6).  
 
1.4.  MCL-1 (myeloid cell leukemia-1) 
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 The mcl-1 gene was originally identified as an early gene induced during 
differentiation of human myeloid leukemia cells (Kozopas et al., 1993). The 
human mcl-1 gene is located on chromosome 1q21 and comprises three exons. 
Alternative splicing gives rise to two distinct MCL-1 mRNAs, MCL-1L and 
MCL-1S, containing or lacking exon 2, respectively (Bingle et al., 2000). The 
absence of exon 2 in MCL-1S causes exon 3 sequences to be translated in a 
different reading frame, so that the C-terminal transmembrane (TM) domain in 
MCL-1L is not included in MCL-1S (MCL-1S/ΔTM). MCL-1S contains 271 
amino acid residues and a BH3 domain only, whereas MCL-1L comprises 350 
amino acid residues and has BH (1-3) domains (Kozopas et al., 1993), as well as a  
C-terminal TM domain that localizes MCL-1L to the OMM (Yang et al., 1995). 
Interestingly, these distinct MCL-1 isoforms have opposing functions in that 
MCL-1L is antiapoptotic, whereas MCL-1S possesses proapoptotic function 
similar to other BH3-only proteins (Bingle et al., 2000). The N-terminal regions 
of MCL-1 contain two PEST domains, rich in proline (P), glutamate (E), serine 
(S), and threonine (T) residues, and are thought to induce rapid protein turnover 
(Rechsteiner and Rogers, 1996; Rogers et al., 1986) and MCL-1 has a short half-
life in cells (Craig, 2002; Nijhawan et al., 2003).  
 
1.4.1  MCL-1 functions 
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 Gene-ablation studies have revealed physiological roles for MCL-1 which 
are markedly divergent from those of other antiapoptotic BCL-2 family members. 
MCL-1 deficient mice display peri-implantation lethality, which is apparently not 
due to increased apoptosis, suggesting that MCL-1 plays a distinct role during 
implantation (Rinkenberger et al., 2000). MCL-1 is also essential for the 
development and maintenance of B and T lymphocytes, as deletion of MCL-1 
during early lymphocyte differentiation increases apoptosis and arrests 
development, while deletion of MCL-1 in mature B and T lymphocytes results in 
rapid apoptosis (Opferman et al., 2003). Furthermore, deletion of MCL-1 in early 
hematopoietic progenitors leads to the severe loss of bone marrow, indicating an 
indispensable role for MCL-1 in hematopoietic stem cell survival (Opferman et al., 
2005). As is the case with other antiapoptotic BCL-2 family members, MCL-1 is 
primarily localized to the OMM and promotes cell survival by blocking MOMP 
via interaction with and neutralization of the multidomain proapoptotic BCL-2 
family members including BAK (Shimazu et al., 2007). Like other antiapoptotic 
BCL-2 family members, MCL-1 interacts with BIM, tBID, BIK, and PUMA, but  
also binds to NOXA and BAK (Chen et al., 2005a; Clohessy et al., 2006; Willis et 
al., 2005). In fact, the BH3-only protein NOXA binds almost exclusively to MCL-
1. The precise molecular mechanism by which MCL-1 promotes cell survival is 
not completely understood. The most plausible mechanism of antiapoptotic action 
of MCL-1 is that MCL-1 sequesters BAK on the OMM, leading to inhibition of 
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BAK oligomerization and MOMP (Shimazu et al., 2007; Willis et al., 2005). 
Upon apoptotic stimuli, Bik, tBID, and NOXA can selectively disrupt MCL-
1/BAK interaction to displace BAK from MCL-1, leading to BAK 
oligomerization and MOMP (Clohessy et al., 2006; Shimazu et al., 2007; Willis et 
al., 2005).  
 
1.4.2  Regulation of MCL-1 
 MCL-1 has a short half-life and is highly regulated at the transcriptional, 
post-transcriptional, translational, and post-translational levels. MCL-1 is 
regulated at the transcriptional level via the transcription factors SRF/ETS, 
STAT3, CREB, and PU.1 (Epling-Burnette et al., 2001; Nijhawan et al., 2003; 
Puthier et al., 1999; Wang et al., 1999), and at the post-transcriptional level 
through alternative splicing leading to accumulation of two distinct MCL-1 
mRNA encoding MCL-1L and MCL-1S isoforms with opposing functions 
(Bingle et al., 2000). MCL-1 is also regulated at the translational level by micro-
RNAs through a mir-29b binding in the 3’-UTR of MCL-1 mRNA (Mott et al., 
2007). Mir-29b directly inhibits expression of MCL-1 by binding to its target 
sequence. The RNA binding protein, CUGBP2, can also bind to the 3’-UTR of 
MCL-1 and inhibit its translation (Subramaniam et al., 2008). Post-translational 
regulation of MCL-1 is mediated by a complex interplay involving three kinases 
(ERK, JNK, and GSK-3β) and at least two E3 ubiquitin ligases (MCL-1 ubiquitin 
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ligase E3 (MULE) and ß-TrCP) (Ding et al., 2007; Domina et al., 2004; Maurer et 
al., 2006; Morel et al., 2009; Mott et al., 2007; Nijhawan et al., 2003). ERK-
mediated phosphorylation of human MCL-1 at Thr-163 prolongs its half-life 
(Domina et al., 2004), although recent studies by Davis and colleagues indicate 
that JNK phosphorylates mouse MCL-1 at Thr-144 (analogous to Thr-163 in 
human MCL-1), which in turn enhances its phosphorylation by GSK-3β at Ser-
140 (Morel et al., 2009).  GSK-3ß-mediated phosphorylation of mouse/human 
MCL-1 at Ser-140/Ser-159 then promotes its ubiquitination by E3 ligases and 
subsequent degradation by the 26S proteasome (Maurer et al., 2006; Morel et al., 
2009). 
 
1.5  p38 MAPKs 
 MAPKs are a family of serine/threonine protein kinases, which are 
activated in response to extracellular stimuli including mitogens, growth factors, 
and environmental stress, and regulate various cellular activities such as gene 
expression, mitosis, differentiation, proliferation, and cell survival/apoptosis. 
Conventional MAPKs consist of three family members: ERKs, JNKs, and p38 
MAPKs and each family member has its own subfamilies: ERKs (ERK1 and 
ERK2), JNKs (JNK1, JNK2, and JNK3), and p38 MAPKs (p38α MAPK, p38ß 
MAPK, p38γ MAPK, and p38δ MAPK) (Chang and Karin, 2001; Davis, 2000; 
Johnson and Lapadat, 2002). An additional MAPK, termed ERK5, has been 
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cloned (Zhou et al., 1995), and ERK5 is a member of a larger MAPK family that 
also includes ERK7 and ERK8 (Abe et al., 1999). However, the functions and 
activation pathways for ERK7 and ERK8 are not fully characterized. The MAPKs 
share a common Tyr-Xaa-Thr dual phosphorylation site in their regulatory loops 
(Hanks and Hunter, 1995). MAPKs are activated through activation pathway, 
comprising a MKKK, MAPK kinase (MKK), and MAPK  (Wagner and Nebreda, 
2009).  
  
1.5.1  Identification of p38 MAPKs 
 Among all p38 MAPKs isoforms, p38α is the best characterized and is 
expressed in most cell types. p38α was first isolated as 38 kDa protein that 
underwent tyrosine phosphorylation in response to endotoxin treatment and 
hyperosmolarity shock (Han et al., 1994), and three additional isoforms were then 
identified: p38ß (Jiang et al., 1996), p38γ (SAPK3/ERK6) (Lechner et al., 1996; 
Mertens et al., 1996), and p38δ (SAPK4) (Goedert et al., 1997; Jiang et al., 1997). 
Of these, p38α and p38ß are ubiquitously expressed (Jiang et al., 1996), while the 
others are differently expressed in different tissues. p38γ is predominantly 
expressed in skeletal muscle (Lechner et al., 1996; Li et al., 1996), and p38δ is 
mainly found in testis, pancreas, and small intestine (Goedert et al., 1997). All 
isoforms have a Thr-Gly-Tyr (TGY) dual phosphorylation motif in the regulatory 
loop between the kinase subdomains (Hanks and Hunter, 1995). p38α and p38ß 
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have high sequence homology (75%) and share sensitivity to pharmacological 
inhibitors such as SB203580, whereas p38γ and p38δ have 60% homology and 
are resistant to SB203580 (Eyers et al., 1999).  
 
1.5.2  Activation and regulation of p38 MAPKs 
 p38 MAPKs are activated by a variety of stimuli such as UV irradiation, 
heat, inflammatory cytokines, and growth factors. Upon stimulation, p38 MAPKs 
are activated through dual phosphorylation of their TGY motif by the MKKs, 
MKK3 and MKK6 (Enslen et al., 1998). Phosphorylated p38 MAPK then goes 
through a characteristic conformational change that alters the alignment of the 
two kinase halves (N- and C-terminal domains), enhancing access to substrates, 
and increasing its enzymatic activity (Bellon et al., 1999). MKK3 and MKK6 are 
activated via phosphorylation by MKKKs. Several MKKKs have been implicated 
in the regulation of p38 MAPK pathways, including mixed lineage protein kinases 
(MLKs), ASK1, TAK1, and some members of MEK kinases (MKKs) (Cheung et 
al., 2003; Ichijo et al., 1997b; Kyriakis and Avruch, 2001; Yamaguchi et al., 
1995). MKKKs responsible for activating p38 MAPKs appear to be cell-type and 
stimulus-specific. p38 MAPKs can also be activated by two alternative MKK-
independent mechanisms. In the first, phosphorylation of p38α is achieved 
through   autophosphorylation and activation following interaction with TAK1-
binding protein 1 (TAB1) (Ge et al., 2002a). Another MKK-independent pathway 
 36 
has been reported in T cells stimulated through the T cell antigen receptor (TCR). 
In this mechanism, p38α is activated by the TCR-stimulated tyrosine kinase ZAP-
70, which phosphorylates p38α at a noncanonical Tyr323 site (Salvador et al., 
2005). Once activated, p38 MAPKs undergo a sequence of phosphorylation to act 
on several downstream substrates, including protein kinases or transcription 
factors, resulting in a wide variety of responses. MAP kinase-activated protein 
kinase 2 (MAPKAPK2) was identified as a p38α substrate (Rouse et al., 1994). 
Moveover, activated MAPKAPK2 phosphorylates various substrates including 
heat shock protein 27 (HSP27) (Stokoe et al., 1992), lymphocyte-specific protein 
1 (LSP1) (Huang et al., 1997), cAMP response element-binding protein (CREB) 
(Tan et al., 1996), activating transcription factor 1 (ATF1) (Tan et al., 1996), 
serum response factor (SRF) (Heidenreich et al., 1999), and tyrosine hydroxylase 
(Thomas et al., 1997). 
 Like all MAPKs, p38 MAPKs are downregulated through 
dephosphorylation by phosphatases. Several phosphatases interact with and 
inactivate p38 MAPKs, including serine/threonine protein phosphatase type 
2Calpha (PP2Calpha) and protein tyrosine phosphatase (PTPase) (Takekawa et al., 
2000; Takekawa et al., 1998). Other studies have suggested that MAPK 
phosphatase (MKP)-1, -4, and -5 can dephosphorylate p38α and p38ß (Camps et 
al., 1998; Muda et al., 1996). Structural studies indicate that a p38 MAPK-
specific pyridinyl imidazole inhibitor, SB203580, binds to the active site of both 
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phosphorylated (active) and unphosphorylated (inactive)  p38α and p38ß isoforms 
in an ATP-competitive manner (Tong et al., 1997). SB203580 binds to an aryl-
specificity pocket normally occupied by the adenine ring of ATP.  
 
1.5.3  Biological consequences of p38 MAPK activation  
 p38 MAPK signaling has been implicated in numerous cellular responses 
from inflammation, cell cycle, and cell death to development, cell differentiation, 
senescence, and tumorigenesis. However, the precise roles of p38 MAPKs in 
many of these processes remain unclear. p38α was first recognized for its role in 
inflammation in regulating the biosynthesis of proinflammatory cytokines such as 
interleukin (IL)-1 and TNFα in endotoxin-stimulated monocytes (Lee et al., 1994). 
Subsequently, it was found to be involved in regulating the production of IL-8 in 
response to IL-1 or osmotic shock and the production of IL-6 in response to TNFα 
(Beyaert et al., 1996; Shapiro and Dinarello, 1995). p38α is also essential for 
embryogenesis, as genetic knockout of p38α results in embryonic lethality due to 
its importance in erythropoiesis and placental angiogenesis (Adams et al., 2000; 
Beyaert et al., 1996; Tamura et al., 2000). Gene-ablation studies indicate that 
p38α is also involved in the proliferation of lung stem and progenitor cells 
(Ventura et al., 2007) and in the differentiation of myoblasts into multinucleated 
myotubes (Perdiguero et al., 2007). p38α can also regulate cell cycle progression, 
both at the G1/S and G2/M transitions, by downregulating cyclins and 
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upregulating cyclin-dependent kinase (CDK) inhibitors (Ambrosino and Nebreda, 
2001).  
 p38α is also involved in tumorigenesis. Genetic modification indicates that 
p38α acts as a tumor suppressor. For instance, constitutive activation of p38 
MAPK, achieved through overexpression of it upstream activators, MKK3 and 
MKK6, results in senescence and suppression of tumorigenesis in several cancer 
cell models (Haq et al., 2002; Wang et al., 2002), and MKK3 and MKK6 double 
knockout fibroblasts are more susceptible to increase tumorigenesis (Brancho et 
al., 2003). Many studies have reported that p38 MAPK signaling is involved in 
apoptosis. However, while p38 MAPK signaling has been shown to promote cell 
death in some cell lines (Porras et al., 2004; Sarkar et al., 2002), in others it  
enhances survival (Liu et al., 2001a; Park et al., 2002). Thus, the role of p38 
MAPK signaling in apoptosis is cell-type specific and stimulus-dependent.  
 
1.6  Dissertation objectives 
 TRAIL has emerged as a promising anticancer therapy, due to its 
remarkable capacity to induce apoptosis in cancer cells with little to no toxicity to 
normal cells (Falschlehner et al., 2009). Therefore, recombinant human TRAIL 
(rhTRAIL) and agonistic monoclonal antibodies to DR4 and DR5 are being 
considered for therapeutic use. Phase I trials have established the safety and 
tolerability of these TRAIL agonists in patients, and Phase II trials are currently 
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evaluating the therapeutic efficacy of TRAIL agonists as single agents or in 
combination with established cancer therapeutics. Many cancers, however, exhibit 
or acquire resistance to TRAIL. Thus, understanding the underlying mechanisms 
that mediate TRAIL resistance is necessary to provide more effective cancer 
treatment. 
 The objective of my dissertation was to understand the primary mechanisms 
responsible for TRAIL resistance in human prostate cancer cells, with a particular 
focus on the role of p38 MAPKs in this process. I hypothesized that TRAIL 
activates a TAK1→MKK3/MKK6→p38 pathway that transcriptionally 
upregulates the expression of MCL-1 and suppresses BAK activation, MOMP, 
and cell death, despite caspase-8 activation and robust BID cleavage. Disruption 
of the p38 MAPK signaling pathway downregulated MCL-1 and sensitized cells 
to TRAIL-induced MOMP and apoptosis. However, reactive oxygen species 
(ROS), generated by injured mitochondria, activated a secondary JNK pathway 
that upregulated MCL-1 expression and afforded partial protection from death.  
Thus, this work demonstrates for the first time that stress kinases activated at 
distinct steps in the extrinsic pathway mediate TRAIL resistance through 





Chapter 2. Materials and Methods 
 
2.1  Reagents and antibodies  
SB203580 (cat. #1020) was obtained from Tocris Bioscience (Ellisville, 
MO), and 5Z-7-oxozeaenol (cat. #NP-009245) was purchased from AnalytiCon 
Discovery GmbH (Potsdam, Germany). TAT-TI-JIP153–163 (cat. #420134) and 
U0126 (cat. #662005) were obtained from Calbiochem (Gibbstown, NJ).  
Antibodies to p-p38 MAPK (Thr-180/Tyr-182; cat. #9211), p-ERK (Thr-202/Tyr-
204; cat. #9101), p-JNK (Thr-183/Tyr-185; cat. #9251), p-MAPKAPK2 (pThr-
222; cat. #3316), p-AKT (Ser-473; cat. #9271), p-MKK3/6 (Ser-189/207; cat. 
#9231), p-TAK1 (Thr-184/Tyr-187; cat. #4531), TAK1 (cat. #4505), BCL-2 (cat. 
#2876), BCL-xL (cat. #2762), BID (cat. #2002), myc tag (cat. #2276), EGFP (cat. 
#2555), and active caspase-3 (cat. #9662) were purchased from Cell Signaling 
Technology (Danvers, MA). FLIP antibody (cat. #ALX-804-127-C100) was 
obtained from Alexis Biochemicals (San Diego, CA), and caspase-8 and 
Smac/DIABLO antibodies were generously provided by Dr. X.-M. Sun and Prof. 
G. M. Cohen (MRC Toxicology Unit, Leicester, UK). Antibodies to FADD (cat. 
#610399) and cytochrome c (cat. #556433) were purchased from BD Biosciences 
(San Jose, CA), and antibodies to MCL-1 (cat. #sc-12756) and actin (cat. #CP01-
100UL) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and 
Oncogene Research Products (Cambridge, MA), respectively. DR5 antibody (cat. 
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#2019) was obtained from ProSci Incorporated (Poway, CA), and antibodies to 
FLAG (cat. #F3165) and Hemagglutinin (cat. #MMS-101P) tags were purchased 
from Sigma-Aldrich (Saint Louis, MO) and Covance (Princeton, NY), 
respectively. RFP/Cherry antibody (cat. #PM005) was obtained from MBL 
International (Woburn, MA).  
 
2.2  Cloning 
The human MCL-1 cDNA encompassing the entire coding region (1.1 kb) 
was amplified by reverse transcription-PCR (RT-PCR) with the following two 
primers (MCL1F: 5’-CCCGAATTCATGTTTGGCCTCAAAAGAAACGC-3’; 
MCL1R: 5’-CCGAGATCTCTATCTTATTAGATATGCCAAACC-3’), digested, 
and cloned into the EcoRI-BglII sites (underlined) of pEGFP-C1 (Clontech, 
Mountain View, CA). The cDNAs of human BAD and NOXA were obtained by 
RT-PCR with the following primers (BADF: 5’-CCGCTCGAGCTATGTTCCA 
GATCCCAGAGTTTG-3’; BADR: 5’-CGCGGATCCTCACTGGGAGGGGGC 
GGAG-3’; NOXAF: 5’-CCGCTCGAGCTATGCCTG GGAAGAAGGCGCG-3’; 
NOXAR: 5’-CGCGGATCCTCAGGTTCCTGAGCAGAAG AG-3’), digested, 
and cloned into the XhoI-BamHI sites (underlined) of pCherry-C1 (Clontech, 
Mountain View, CA).  For the generation of shRNAs, oligonucleotides to MCL-1 
(sense: 5’-GATCCCCAGTCCGATTACCGCGTTTCTTCAAGAGAGAAACG 
CGGTAATCGGACTTTTTTTC-3’; antisense: 5’-TCGAGAAAAAAAGTCCG 
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ATTACCGCGTTTCTCTCTTGAAGAAACGCGGTAATCGGACTGGG-3’) or 
a scrambled control (sense: 5’-GATCCCCACCGTCGATTTCACCCGGGTTCA 
AGAGACCCGGGTGAAATCGACGGTTTTTTTC-3’; antisense: 5’-TCGAGA 
AAAAAACCGTCGATTTCACCCGGGTCTCTTGAACCCGGGTGAAATCGA 
CGGTGGG-3’) were annealed to generate sticky ends (underlined) and 
immediately cloned into the BamHI-XhoI sites of pSuper.retro.puro (OligoEngine, 
Seattle, WA). The boxed sequence corresponds to the 9-nt hairpin that is 
generated following transcription.   
A cDNA encoding p38α (kindly provided by Dr. Kevin N. Dalby, The 
University of Texas at Austin, Austin, TX) was subcloned into pcDNA6 with an 
N-terminal myc tag (Invitrogen, Carlsbad, CA), and a kinase-dead (D168A) 
mutant was subsequently incorporated by site-directed mutagenesis. A 
constitutively-active mutant of p38α (D176A/ F327S; obtained from Prof. David 
Engelberg, Hebrew University, Israel)(Askari et al., 2007) was subcloned into the 
XhoI-BamHI sites of the pEGFP-C1 and pCherry-C1 vectors (Clontech, Mountain 
View, CA), and an SB203580-resistant mutation (T106M) was incorporated by 
site-directed mutagenesis (Eyers et al., 1999). Dominant-negative mutants of 
TAK1 (K63A), MKK3 (S189A/T193A), and MKK6 (S207A/T211A) were 
generously provided by Dr. Xin Lin (University of Texas, M. D. Anderson Cancer 
Center, Houston, TX) and Dr. Jiahuai Han (Scripps Research Institute, La Jolla, 
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CA) (Blonska et al., 2005; Ge et al., 2002b). pEBB-ubiquitin-Smac/DIABLO, 
which is designed to express a mature form of Smac in the cytosol, was provided 
by Dr. Colin S. Duckett (University of Michigan Medical School, Ann Arbor, MI) 
(Hunter et al., 2003). Wild-type caspase-9 was cloned into the FG9 lentiviral 
vector (kindly provided by Dr. Casey W. Wright, UT-Austin, Austin, TX), and a 
dominant-negative mutation (C287A) was incorporated by site-direct mutagenesis.   
  
2.3  Cell culture and Transfections 
DU145 prostate cancer cells were grown in RPMI-1640, supplemented 
with 5% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 5% 
Fetalplex (Gemini Bio-products, West Sacramento, CA), 1% penicillin-
streptomycin (100 units/mL), and 2 mM glutamine. Cells were maintained at 
37°C in humidified air containing 5% CO2 and were routinely passaged every 3 
days. For transient transfections, cells were transfected with 1 μg/mL plasmid 
DNA using TransIT®-LT1 transfection Reagent (Mirus Bio, Madison, WI). For 
stable transfections, cells were selected for 10 days in 1 μg/mL of puromycin and 
then isolated as individual clones.   
 
2.4  Quantitation of apoptosis 
Cells were harvested by trypsinization, washed with PBS, and resuspended 
in annexin-V binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM 
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CaCl2) containing annexin-V-fluorescein isothiocyanate (FITC) and propidium 
iodide (PI; Roche Applied Sciences, Indianapolis, IN).  Annexin V was expressed, 
labeled with FITC, and purified in-house.  FITC- and/or propidium iodide-labeled 
cell populations were analyzed by flow cytometer (Beckman-Coulter, Fullerton, 
CA). 
 
2.5  DEVDase assay 
Cells were pretreated with SB203580 (50 µM) for 2 h, cotreated with 
TRAIL (500 ng/ml) for an additional 8 h, and collected for analysis. The cells 
were then washed twice with PBS, resuspended in lysis buffer (50 mM Tris, 
pH7.5, 1 mM EDTA, 10 mM EGTA, 10 µM digitonin), and incubated for 10 min 
at 37°C.  Cytosolic fractions were obtained by centrifugation at 15,000 x g for 10 
min and were subsequently incubated for 30 min at 37°C with an equal volume of 
assay buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% NP-40, 5 mM 
MgCl2) containing the fluorescent substrate, Asp-Glu-Val-Asp-7-amino-4-
methylcoumarin (DEVD-AMC). DEVDase activities were measured 
(λex/λem = 360/450 nm) in a 96-well plate format using a Wallac Victor3 
1420 Multilabel counter (Waltham, MA). To confirm the effectiveness of our 
dominant-negative (DN) caspase-9 (C287A) construct, lysates were prepared 
from cells stably expressing caspase-9-DN and activated by adding cytochrome c 
(10 µM), dATP (2 mM), and MgCl2 (2 mM).  Following a 30 min incubation at 
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37°C, DEVD-AMC was added and all samples were assayed for DEVDase 
activity (Bratton et al., 2000). 
 
2.6  Digitonin-based subcellular fractionation 
Cells, treated with TRAIL ± SB203580 (as described above), were 
assayed for MOMP, essentially as previously described (Milleron and Bratton, 
2006).  Briefly, cells were washed with PBS and lysed for 10 min on ice in 100 
µL of digitonin lysis buffer (75 mM KCl, 1 mM NaH2PO4, 8 mM Na2HPO4, 250 
mM sucrose, 60 µg/mL of digitonin) containing protease inhibitors (1 mM PMSF, 
2 µg/mL of aprotinin, 2  µg/mL of leupeptin, 2 µg/mL of pepstatin). The cells 
were then pelleted by centrifugation at 15,000 x g for 10 min, and the supernatant 
(cytosol) was obtained. The remaining pellet (mitochondria) was then 
resuspended in lysis buffer (20 mM Tris-HCl, 135 mM NaCl, 10% glycerol, 50 
mM NaF, 5 mM Na3VO4, 0.2% NP-40) with protease inhibitors for 20 min on ice.  
Finally, the supernatant and pellet fractions were immunoblotted with an antibody 
to cytochrome c.   
 
2.7  Isolation of TRAIL receptor signaling complexes 
Cells were pretreated with SB203580 (50 µM) for 2 h, followed by a 30 
min treatment with biotinylated TRAIL (bTRAIL; 500 ng/ml). The cells were 
then washed three times with ice-cold PBS to remove any unbound ligand and 
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lysed for 30 min on ice in 3 mL of lysis buffer [30 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 10 mM glycerophosphate, 
1 mM sodium orthovanadate, 5 mM NaF] with protease inhibitors (1mM PMSF, 2 
µg/mL of aprotinin, 2 µg/mL of leupeptin, 2 µg/mL of pepstatin). Lysates were 
cleared by centrifugation at 13,000 x g for 30 min and bTRAIL complexes 
precipitated overnight at 4ºC using streptavidin-conjugated to SepharoseTM beads 
(Amersham Biosciences, Pittsburgh, PA). After overnight incubation, the beads 
were washed four times with lysis buffer, and 60 µL of 2X Laemmli sample 
buffer were added to the beads. 
 
2.8  Quantitative RT-PCR 
Cells were plated at a density of 0.6 x 106 cells.  After 24h, the cells were 
treated with different combination treatments at the indicated time points. Total 
RNA was extracted using Qiagen RNeasy Mini kit (Valencia, CA), and reverse 
transcription was performed from 2 µg of total RNA using oligo-dT and AMV 
reverse transcriptase (Promega, Madison, WI), according to the manufacturer’s 
instructions. The primer sequences were designed as follows: qMCL1F: 5’-
AAGCCAATGGGCAGGTC T-3’; qMCL1R: 5’-TGTCCAGTTTCCGAAGCA       
T-3’; qGAPDHF: 5’-TGCACCACCAACTGCTTAGC-3’; qGAPDHR: 5’-GG 
CATGGACTGTGGTCATGAG-3’(Juo et al., 1998).  Quantitative RT-PCR was 
performed with SYBR Green dye using an ABI 7900HT (Perkin-Elmer Applied 
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Biosystems, Foster City, CA), according to the manufacturer’s instructions.  PCR 
reactions were performed in triplicate, and the relative amount of MCL-1 cDNA 
was calculated by the comparative CT method (Livak and Schmittgen, 2001).  CT 
values obtained for the different samples were normalized to corresponding CT 
values of GAPDH.   
 
2.9  Western blot analysis 
After SDS-PAGE, proteins were transferred to Hybond-N Nitrocellulose 
(Amersham Biosciences, Pittsburgh, PA). Membranes were blocked in Tris-
buffered saline (TBS) containing 5% non-fat dry milk and 0.1% Tween 20 (TBS-
T), prior to incubation with the primary antibody for 1 h. The membranes were 
then washed with TBS-T followed by exposure to the appropriate horseradish 
peroxidase-conjugated secondary antibody for 1h. Immunostained proteins were 
visualized on Kodak x-ray film using the enhanced chemiluminescence (ECL) 
detection system (Amersham Biosciences, Pittsburgh, PA).   
 
2.10  ROS Quantification 
To measure ROS, cells were pretreated with SB203580 (50 µM) for 2 h ± 
zVAD-fmk (50 µM) for 1 h.  TRAIL (500 ng/ml) was then added for 8 h and 
incubated with 2’,7’-dichlorodihydrofluorescein diacetate (DCFDA, 10 μM; 
Molecular Probes, Carlsbad, CA) for 30 min. Excess DCFDA was removed by 
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washing the cells twice with PBS at room temperature, and labeled cells were 
then trypsinized, rinsed, and resuspended in PBS.  Oxidation of DCFDA to the 
highly fluorescent 2’,7’-dichloro-fluorescein (DCF) is proportionate to ROS 
generation and was analyzed by flow cytometry. To measure mitochondrial-
generated ROS, pHyPer-Mito, a mitochondrial-localized oxidant-activated 
fluorescent protein, was transfected into cells and cells were treated TRAIL ± 
SB203580 (as described above). Fluorescence intensity, corresponding to H2O2 
generated in the mitochondria, was analyzed by flow cytometry, and images were 
captured by fluorescence microscopy. 
 
2.11  BAK activation assay 
To detect activated BAK, control and treated cells were fixed for 5 min in 
0.25% paraformaldehyde, washed twice with PBS, and incubated for 30 min at 
room temperature in a PBS buffer containing 100 µg/mL digitonin and a 
conformation-specific mouse anti-BAK antibody (1:30; AM03, Calbiochem, 
Gibbstown, NJ).  Cells were then washed, incubated with 0.25 µg of Alexa Fluor 
488 goat anti-mouse antibody (Invitrogen, Carlsbad, CA) for 30 min in the dark, 





Chapter 3. TRAIL-activated p38 MAPK pathway suppresses apoptosis 
through transcriptional upregulation of MCL-1 in human prostate  
cancer cells 
 
3.1  Introduction 
Prostate cancer is the most common type of cancer found in American 
men. As the second leading cause of cancer-related deaths, it has been estimated 
that there will be about 192,280 new cases of prostate cancer and approximately 
27,360 men will die of this disease in 2009 (American Cancer Society, 2009).  
A multicellular organism maintains cellular homeostasis in normal tissue 
compartments and eliminates disordered cells by a controlled cellular mechanism 
known as apoptosis (Kerr et al., 1972). Apoptosis can be induced by various 
stimuli, and radiation or chemicals in particular have been used in cancer therapy. 
There are two signaling pathways that lead to the activation of apoptosis: the 
extrinsic and intrinsic pathways. The intrinsic pathway, controlled by BCL-2 
family members, has a substantial role in chemotherapy and radiation-induced 
cell death. By contrast, the extrinsic pathway is initiated through apoptotic signal 
transduction cascades mediated by members of TNF family (Cotter, 2009). Thus, 
death ligands have been considered as potentially useful new therapeutics. In 
particular, TRAIL has emerged as a promising anticancer therapy, due to its 
remarkable capacity to induce apoptosis in cancer cells with little to no toxicity to 
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normal cells (Falschlehner et al., 2009). Several different agents related to TRAIL 
(recombinant human TRAIL and agonistic monoclonal antibodies to TRAIL 
receptors) have been developed and are being tested in human clinical trials. 
Although these agents are promising, their utility is limited to patients with 
TRAIL-sensitive tumors. Unfortunately, many tumors, including human prostate 
tumors, possess or acquire resistance to TRAIL. Over the last decade many 
studies have proposed the intracellular mechanisms responsible for TRAIL 
resistance. The precise mechanisms, however, remain unclear, although it is now 
clear that the resistance can be caused by numerous factors acting at several 
different steps in the TRAIL signaling pathway. Expression of TRAIL “decoy” 
receptors, TRAIL-R3 and TRAIL-R4, has been proposed to mediate TRAIL 
resistance by competing with TRAIL-R1 and TRAIL-R2 for binding to TRAIL 
(LeBlanc and Ashkenazi, 2003), and at high expression levels, cellular FLICE-
like inhibitory protein (c-FLIP) inhibits apoptosis by competing with caspase-8 
for binding to FADD (Clarke and Tyler, 2007; Geserick et al., 2008; Irmler et al., 
1997). Finally, overexpression of antiapoptotic BCL-2 family members, including 
BCL-2, BCL-XL, and MCL-1, is often associated with TRAIL resistance (Fulda 
et al., 2002; Hinz et al., 2000; Ricci et al., 2007), particularly in Type II cells, due 
to their abilities to prevent MOMP and the release of cytochrome c or 
Smac/DIABLO (Bratton and Cohen, 2003). 
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In Type I cells, the apoptotic signal from active caspase-8 is sufficient to 
activate the downstream effector procaspase-3 and induce apoptosis.  However, in 
Type II cells, there is insufficient activation of procaspase-3—or caspase-3 is 
inhibited by IAP , such as XIAP—so that the apoptotic signal must be further 
amplified by engaging the intrinsic  pathway (Bratton and Cohen, 2003; Scaffidi 
et al., 1999). In this instance, caspase-8 cleaves and activates the BH3-only 
protein BID, which in turn induces MOMP, causing the release of additional 
apoptogenic proteins, including the IAP antagonist, second mitochondrial 
activator of caspases Smac/DIABLO and cytochrome c, the latter of which 
activates yet another caspase-activating complex, known as the Apaf-1•caspase-9 
apoptosome (Bratton and Cohen, 2003). Therefore, inhibition of MOMP is able to 
cause resistance to TRAIL.  
In the present study, I have investigated the role of p38 MAPK in the 









3.2  Results 
 
3.2.1  TRAIL activates an antiapoptotic TAK1→MKK3/MKK6→p38 MAPK 
signaling pathway in resistant prostate cancer cells 
 In an effort to determine the mechanism(s) of TRAIL resistance in human 
prostate cancer cells, DU145 cells were exposed to recombinant TRAIL and 
examined for activation of various stress and growth-related kinases (Fig. 3.1A). 
Notably, p38α and its downstream target, MAPKAPK2, were activated within 2 h 
of treatment (prior to cell death), whereas other stress kinases such as JNKs were 
only weakly activated at later time points (Fig. 3.1A). ERKs were constitutively-
active in naive cells, but TRAIL did not enhance their activation, nor did it 
activate AKT/PKB (Fig. 3.1A; data not shown). The importance of p38α 
activation was evident when cells were cotreated with TRAIL and the selective 
p38α and p38ß inhibitor, SB203580, as the combination led to a significant 
increase in apoptosis (Fig. 3.1B). To examine whether the apoptosis was caspase-
dependent, the pan-caspase inhibitor zVAD-fmk was used. Cell death induced by 
the combination of TRAIL and SB203580 was completely prevented by zVAD-
fmk, and the cell death was similar to that of untreated control cells (Fig. 3.1B). 
Consistent with this result (Fig. 3.1B), TRAIL activated the initiator caspase-8 
and the effector caspase-3 (as determined by caspase processing and DEVDase 
activity), particularly in the presence of SB203580 (Fig. 3.1C). Cell death was 
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Figure 3.1  Inhibition of TRAIL-activated p38 MAPKs sensitizes cells to 
TRAIL-induced apoptosis in a caspase-dependent manner. 
 
(A) DU145 prostate cancer cells were treated with recombinant TRAIL (500 
ng/mL) for 0.5-8 h, and cells were immunoblotted for various active 
phosphorylated kinases, including p-p38α, p-MK2, p-JNK, and p-ERK. (B and C) 
Cells were treated with TRAIL ± SB203580 (50 μM) ± zVAD-fmk (50 μM) and 
assayed for cell death by Annexin V/PI staining and flow cytometry. Each bar 
represents the mean of three separate experiments ± SEM. Cells were also 
immunoblotted for phosphorylated p38, as well as active caspase-8 (p18 large 
subunit) and caspase-3 (p20, p19, and p17 large subunits). Caspase-3/7 DEVDase 











                             








Figure 3.2 TRAIL sensitization is due to specific inhibition of p38 MAPKs.  
 
(A and B) DU145 cells were transiently transfected with expression plasmids 
encoding EGFP, constitutively-active p38α (EGFP-p38α-CA), or p38α-CA 
containing a T106M mutation [EGFP-p38α-CA (T106M)]. Cells were then 
exposed to TRAIL for 8 h, stained with Hoechst 33258, and assayed for apoptosis 
by measuring the percentage of GFP+ cells with condensed nuclei using 
fluorescence microscopy. Each bar represents the mean of three separate 
experiments ± SEM. (C) Crystal structure of p38α with SB203580 occupying its         
ATP binding pocket. 
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fully inhibited by zVAD-fmk; however, this polycaspase inhibitor had no effect 
on the activation of p38α, further establishing p38α activation as an early 
upstream event (Fig. 3.1B; Fig. 3.1C, top panel, lanes 5-8). This was an important 
observation, because although few studies have addressed how TRAIL activates 
p38α, the adapter protein RIP1 and caspase-8 activity were thought to be essential 
(Varfolomeev et al., 2005).  
To examine whether the cell death caused by cotreatment with TRAIL 
plus SB203580 was p38α-dependent, cells were transiently transfected with 
expression plasmids encoding EGFP, constitutively-active (D176A/F327S) p38α 
(EGFP-p38α-CA), or p38α-CA containing a T106M “gate-keeper” mutation 
[EGFP-p38α-CA (T106M)]. The sensitization of DU145 cells to TRAIL was due 
to specific inhibition of p38 MAPKs, as transfection of cells with a constitutively-
active form of p38α (CA) largely rescued cells from TRAIL/SB203580-induced 
cell death, but only when accompanied by a mutation in the “gate-keeper” residue 
(T106M), which lowers the affinity of SB203580 for the ATP-binding pocket (Fig. 
3.2A, C) (Eyers et al., 1999).  EGFP-p38α-CA undergoes autophosphorylation 
and phosphorylates endogenous p38α, but is sensitive to SB203580, whereas 
EGFP-p38α-CA (T106M) is only weakly inhibited by SB203580 (Fig. 3.2B).  
Since TNF reportedly activates p38α through the activation of TAK1 or 
ASK1 (Cheung et al., 2003; Ichijo et al., 1997a; Tobiume et al., 2001; Wang et al., 
2001), we next sought to determine if either of these MKKKs was essential for 
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Figure 3.3 TRAIL activates a TAK1→MKK3/6→p38 MAPK pathway that 
suppresses apoptosis. 
 
(A and B) Cells were cotreated with TRAIL ± 5Z-7-oxozeaenol (1 μM) ± zVAD-
fmk (50 μM) and were blotted for phosphorylated p-TAK1 and p-p38. In addition, 
cells were treated with TRAIL ± 5Z-7-oxozeaenol or SB203580 and were assayed 
for cell death by Annexin V/PI staining and flow cytometry. (C) DU145 cells 
were transiently transfected with pEGFP for 24 h, along with empty vectors, or 
those expressing dominant-negative mutants of TAK1, MKK3, MKK6, or p38α. 
Cells were then exposed to TRAIL for 8 h, stained with Hoechst 33258, and 
assayed for apoptosis by measuring the percentage of GFP+cells with condensed 
nuclei. Cell lysates were also immunoblotted for FLAG-TAK1-DN, HA-MKK3-
DN, HA-MKK6-DN, Myc-p38-DN, and endogenous p-p38α. 
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TRAIL-mediated activation of p38α. Exposure of DU145 cells to TRAIL resulted 
in the phosphorylation/activation of TAK1 within ~30-60 min, prior to (or 
concomitant with) activation of p38α (Fig. 3.1A; Fig. 3.3A, inset), and did so in a 
caspase-independent manner (Fig. 3.3B, lanes 1, 2 and 4), whereas ASK1 failed 
to undergo phosphorylation at Thr-845 (data not shown). 5Z-7-oxozeaenol, a 
resorcylic lactone of fungal origin, has been reported to selectively inhibit TAK1 
(Ninomiya-Tsuji et al., 2003; Yao et al., 2007). Therefore, we pretreated cells 
with 5Z-7-oxozeaenol and found that it inhibited TRAIL-induced activation of 
TAK1 and p38α (Fig. 3.3B, lanes 1-3 and 5), and correspondingly, potentiated 
TRAIL-induced apoptosis at levels comparable to TRAIL plus SB203580 (Fig. 
3.3A). Finally, to confirm our results with 5Z-7-oxozeaenol, we determined the 
effects of dominant-negative TAK1 (K63A) and p38α (D168A) mutants on 
TRAIL-induced activation of p38α and apoptosis in DU145 cells (Fig. 3.3C). 
Dominant-negative MKK3 (S189A/T193A) and MKK6 (S207A/T211A) mutants 
were also examined, as these two MKKs play redundant but essential roles in 
TNF-dependent activation of p38 MAPKs (Brancho et al., 2003). As expected, 
disruption of the TAK1 → MKK3/MKK6 → p38 MAPK pathway, at any step, 
suppressed the phosphorylation/activation of p38α and resulted in significant 










Figure 3.4 TRAIL mediates the activation of both a prosurvival and 
prodeath pathways. 
 
Scheme of the antiapoptotic TAK1→MKK3/MKK6→p38 MAPK and 







3.2.2 p38 MAPKs suppress TRAIL-induced apoptosis downstream of the 
DISC by inhibiting MOMP and the release of Smac/DIABLO 
 Our initial results suggested a simple model, wherein TRAIL receptor 
stimulation resulted in the activation of a prosurvival TAK1 → MKK3/MKK6 → 
p38 MAPK pathway and a prodeath TRAIL-R1/TRAIL-R2 → FADD → caspase-
8 pathway (Fig. 3.4). It remained unclear, however, how p38α activation 
prevented apoptosis. To address this question, we first analyzed the effects of 
SB203580 on formation of the TRAIL DISC. As shown in Fig. 3.5A, SB203580 
had no effect on the recruitment of the adapter protein FADD to TRAIL-R2, or 
the subsequent recruitment and activation of the initiator procaspase-8 (Fig. 3.5A). 
FLIP overexpression, which can inhibit the activation of procaspase-8 within the 
DISC and is often cited as a cause of TRAIL resistance, was likewise unaffected 
by SB203580 (Fig. 3.5B). In contrast, an examination of mitochondria revealed 
that inhibition of p38 MAPKs was required for TRAIL-induced MOMP, as 
determined by the mitochondrial release of cytochrome c and Smac/DIABLO into 
the cytosol (Fig. 3.6).   
  Cytochrome c induces formation of the apoptosome and sequential 
activation of caspases-9 and -3 (Bratton et al., 2000). However, in the case of 
death receptor stimulation, it is often the release of Smac/DIABLO, rather than 
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Figure 3.5  p38 MAPKs have no effect on TRAIL DISC formation or basal 
FLIP expression. 
 
(A) DU145 cells were treated with biotinylated-TRAIL (bTRAIL; 500 ng/mL) ± 
SB203580 (50 μM), and DISC analyses were performed as described in the methods. 
Note, the unstimulated control (U/S) was obtained by adding bTRAIL to lysed control 
cells to rule out nonspecific ligand interactions. (B) Cells were treated with TRAIL ± 











Figure 3.6  p38 MAPKs inhibit MOMP. 
Cells were treated with TRAIL ± SB203580, and mitochondrial pellets or 




















Figure 3.7  The release of Smac/DIABLO, rather than cytochrome c, is 
essential for TRAIL-induced apoptosis. 
 
(A and B) DU145 cells were infected with empty virus or virus expressing a 
dominant-negative caspase-9, treated with TRAIL ± SB203580, and assayed for 
cell death by Annexin V/PI staining and flow cytometry. Each bar represents the 
mean of three separate experiments ± SEM. To confirm the effectiveness of the 
dominant-negative caspase-9, naive lysates from infected cells were incubated 
with cytochrome c and dATP and assayed for caspase-3/-7 DEVDase activity. (C) 
DU145 cells were transiently transfected with pEGFP for 24 h, along with pEBB-
ubiquitin or pEBB-ubiquitin-Smac/DIABLO, and the cells were then exposed to 
TRAIL ± SB203580 for 8 h, stained with Hoechst 33258, and assayed for the 
percentage of GFP+ apoptotic cells. Each bar represents the mean of three 
separate experiments ± SEM. NS, denotes a lack of statistical significance. 
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cytochrome c, that is critical for cell killing. In these instances, active caspase-8 
processes procaspase-3, but caspase-3 is inhibited by IAPs, and cytosolic 
Smac/DIABLO is required to antagonize IAPs and relieve the inhibition of 
caspase-3 (Bratton and Cohen, 2003). We therefore stably infected cells with a 
lentivirus expressing dominant-negative caspase-9 (C287A), a potent inhibitor of 
the apoptosome (Choi et al., 2009), or transiently transfected cells with a 
ubiquitin-Smac/DIABLO fusion construct that produces mature cytosolic 
Smac/DIABLO (Hunter et al., 2003). To confirm the effectiveness of the 
dominant-negative caspase-9, lysates from untreated cells were assayed for 
apoptosome activity in response to the addition of cytochrome c and dATP. 
Overexpression of dominant-negative caspase-9 had little effect on 
TRAIL/SB203580-induced apoptosis in DU145 cells (Fig. 3.7B), even though it 
clearly inhibited the activation of endogenous caspase-9 in cytochrome c/dATP-
activated lysates (Fig. 3.7A). Smac/DIABLO, on the other hand, dramatically 
potentiated TRAIL-induced cell death, even in the absence of SB203580 (Fig. 
3.7C). Thus, the TAK1 → MKK3/MKK6 → p38 MAPK pathway appeared to 
suppress TRAIL-induced apoptosis by preventing MOMP and the release of 
Smac/DIABLO. 
 
3.2.3 p38 MAPKs inhibit TRAIL-induced MOMP, in spite of BID activation, 
through transcriptional upregulation of MCL-1 
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     Death receptors normally engage the mitochondrial pathway through caspase-
8-dependent cleavage and activation of the proapoptotic BH3-only protein, BID 
(Chai et al., 2000; Li et al., 1998; Luo et al., 1998). Though controversial, 
truncated BID (tBID) and other BH3-only proteins then directly activate the 
multidomain proapoptotic BCL-2 family members, BAX or BAK (direct 
activation model), and/or antagonize the antiapoptotic Bcl-2 family members, 
BCL-2, BCL-XL, or MCL-1, thereby relieving their inhibition of BAX and BAK 
(indirect activation model) (Youle and Strasser, 2008). We treated DU145 cells 
with TRAIL ± SB203580 and examined them for BID cleavage and downstream 
BAK activation. Remarkably, exposure to TRAIL alone induced near complete 
cleavage of BID (Fig. 3.8A, lane 5), but in the absence of SB203580, tBID failed 
to induce the conformational change in BAK required for its activation (Fig. 
3.8B). Thus, consistent with our previous DISC results, TRAIL receptor 
stimulation induced significant caspase-8 activation and BID cleavage, but tBID 
was unable to induce BAK oligomerization and MOMP unless the antiapoptotic 
p38 MAPK pathway was disrupted (Fig. 3.5A; Fig. 3.6; Fig. 3.8A, B).   
Given the aforementioned results, we considered that p38 MAPKs might 
regulate the expression of BCL-2, BCL-xL, or MCL-1. Indeed, following 
treatment with SB203580, basal MCL-1 (but not BCL-2 or BCL-xL) expression 
levels were reduced, both at the protein and transcriptional levels (Fig. 3.9A, lanes 
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Figure 3.8  Inhibition of p38 MAPKs is required for MOMP, in spite of Bid 
activation. 
 
(A) DU145 cells were treated with TRAIL (500 ng/mL) ± SB203580 (50 μM) ± 
zVAD-fmk (50 μM), immunoblotted for BID cleavage, and (B) assayed for BAK 
activation by flow cytometry using an epitope-specific antibody that recognizes 





































Figure 3.9  p38 MAPKs regulate the transcription of MCL-1. 
 
(A and B) Cells were treated with TRAIL ± SB203580 and assayed for expression 
of antiapoptotic multidomain BCL-2 family members, MCL-1, BCL-2, and BCL-
XL, at the protein (immunoblotting) and/or transcriptional (qRT-PCR) levels. (C 
and D) Time-course experiments were performed (as described above) to assess 




1 and 2; Fig. 3.9B), whereas TRAIL treatment alone led to an increase in MCL-1 
expression (Fig. 3.9A, lanes 1 and 3; Fig. 3.9B). Surprisingly, when used in 
combination, MCL-1 levels were largely maintained, but it was important to note 
that these assays were performed at 8 h, when the combination of TRAIL plus 
SB203580 induced significant apoptosis (Fig. 3.9A, lane 4; Fig. 3.9B).  
Subsequent time-course experiments revealed that SB203580 suppressed the basal 
and upregulated expression of MCL-1 by TRAIL during the first 2-3 h of 
treatment and that MCL-1 levels did not rebound until later (≥ 4 h) after the 
activation of caspases (Fig. 3.9C, lanes 4-8; Fig. 3.9D). Thus, in the presence of 
SB203580, cells were sensitized to TRAIL for at least 3-4 h, although recovery of 
Mcl-1 levels by 4 h after TRAIL treatment may have protected some cells from 
death. To confirm that the loss of MCL-1 expression was due to a decrease in 
transcription and was not the result of an increase in protein turnover, we 
transiently expressed MCL-1 from a CMV promoter and followed the turnover of 
MCL-1 in the presence of cycloheximide, an inhibitor of protein synthesis. Since 
ERK-dependent phosphorylation of MCL-1 at Thr-163 has been shown to 
regulate the turnover of MCL-1 (Domina et al., 2004), we compared the effects of 
SB203580 with the ERK inhibitor, U0126. As shown, in Fig. 3.10, while 
treatment with U0126 led to rapid turnover of MCL-1 (lower panels), inhibition 











Figure 3.10  p38 MAPKs have no effect on MCL-1 turnover. 
 
(G) DU145 cells were transiently transfected with pcDNA3-MCL-1 for 24 h, after 
which cycloheximide (CHX; 1μM) was added, along with either SB203580 (50 
μM) or the ERK inhibitor U0126 (10 μM). Turnover was then assessed by 
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Figure 3.11  MCL-1 mediates TRAIL resistance.  
 
(A) DU145 cells were transiently transfected with pEGFP or pEGFP-MCL-1 for 
24 h (see inset for immunoblot of expressed proteins), exposed to TRAIL ± 
SB203580 for 8 h, stained with Hoechst 33258, and assayed for the percentage of 
GFP+ apoptotic cells. Each bar represents the mean of three separate experiments 
± SEM. (B) DU145 cells were transfected with pSuper-scramble or pSuper-MCL-
1 to stably knockdown the expression of MCL-1 by RNA interference (see inset 
for knockdown of MCL-1). Cells were then exposed to TRAIL ± SB203580 and 
assayed for cell death by Annexin V/PI staining and flow cytometry. Each bar 
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Figure 3.12  Overexpression of NOXA potentiates TRAIL-induced apoptosis. 
 
(A and B) DU145 cells were transiently transfected with pmCherry, pmCherry-
NOXA, or pmCherry-BAD for 24 h (see inset for immunoblot of expressed 
proteins), exposed to TRAIL ± SB203580 for 8 h, stained with Hoechst 33258, 
and assayed for the percentage of mCherry + apoptotic cells. Each bar represents 
the mean of three separate experiments ± SEM. 
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collectively, the data argued strongly that p38 MAPK activity regulated the 
expression of MCL-1 at the transcriptional level.  
 We next confirmed the importance of MCL-1 for mediating TRAIL 
resistance using several approaches. Firstly, we found that ectopic expression of 
EGFP-MCL-1 significantly inhibited cell death induced by TRAIL plus 
SB203580 (Fig. 3.11A), whereas selective downregulation of endogenous MCL-1 
by RNA interference sensitized cells to TRAIL alone, at a level comparable to 
scrambled control cells treated with TRAIL plus SB203580 (Fig. 3.11B).  
Secondly, since the BH3-only proteins, NOXA and BAD, selectively antagonize 
MCL-1 and BCL-2/BCL-XL/BCL-W, respectively (Chen et al., 2005b), we 
expressed NOXA or BAD as Cherry fusion proteins and found that only NOXA 
sensitized DU145 cells to TRAIL (Fig. 3.12A, B). Thus, while TRAIL receptor 
stimulation led to near complete cleavage of BID, the intracellular concentration 
of tBID was apparently insufficient to fully antagonize MCL-1 and alleviate the 
inhibition of BAK by MCL-1; or alternatively, MCL-1 sequestered all of the 
available tBID and prevented its activation of BAK. Consistent with either 
interpretation, ectopic overexpression of tBID-EGFP induced significant 
apoptosis, but when combined with SB203580 (which inhibited basal p38 activity 
and downregulated basal MCL-1 levels), ~90% of the cells underwent apoptosis 













Figure 3.13  SB203580 sensitizes cells to tBid-induced apoptosis. 
 
DU145 cells were transiently transfected with EGFP or tBID-EGFP for 24 h (see 
inset for immunoblot of expressed proteins), exposed to DMSO or SB203580 for 
8 h, stained with Hoechst 33258, and assayed for the percentage of GFP+ 






→ MKK3/MKK6 → p38 MAPK pathway was required to downregulate MCL-1 
and facilitate tBID-induced BAK activation, MOMP, and cell death. 
 
3.3  Discussion 
TNF receptor stimulation activates various antiapoptotic signaling 
pathways that typically subvert an otherwise proapoptotic extrinsic pathway, 
resulting in minimal (if any) death in most cell-types (Wajant et al., 2003). 
TRAIL receptor stimulation, by comparison, induces apoptosis selectively in 
tumor cells, but unfortunately ~50% of tumors possess or acquire resistance to 
TRAIL. Previous studies have shown that TRAIL, like TNF, activates ERK, JNK, 
and p38 kinases, but the magnitude of the responses is generally modest, and it 
remains unclear if these pathways play significant roles in mediating TRAIL 
resistance. In this study, we have found that stimulation of TRAIL receptors 
activates p38α that is responsible for resistance to apoptosis (Fig 3.1; Fig. 3.2). 
We next questioned how p38α was activated through TRAIL. Since TNF 
reportedly activates p38α through the activation of MLKs, TAK1 or ASK1 
(Cheung et al., 2003; Ichijo et al., 1997a; Tobiume et al., 2001; Wang et al., 2001) 
we sought to determine if either of these MKKKs was essential for TRAIL-
mediated p38α activation. We have observed that TAK1 → MKK3/MKK6 → 
p38 MAPK pathway that suppresses apoptosis is activated upon TRAIL 
stimulation (Fig. 3.3). Taken together, our data suggest that TRAIL receptor 
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stimulation leads to the activation of an antiapoptotic TAK1 → MKK3/MKK6 → 
p38 MAPK pathway and a proapoptotic TRAIL-R1/TRAIL-R2 → FADD → 
caspase-8 pathway, and the antiapoptotic pathway induced by TRAIL inhibits the 
TRAIL-activated proapoptotic pathway.   
 The mechanism by which p38 MAPKs prevented apoptosis in DU145 
prostate cancer cells, however, remained unclear. To address this question, we 
tested the effect of p38 MAPKs inhibition on TRAIL DISC formation and the 
expression of FLIP, which is often cited as a cause of TRAIL resistance. No 
effects were observed (Fig. 3.5). However, an examination of mitochondria 
revealed that inhibition of p38 MAPKs was essential for TRAIL-induced MOMP 
(Fig. 3.6). Indeed, consistent with previous studies in other cancer cell types, from 
our laboratory and others, we found that release of Smac (rather than cytochrome 
c) was essential for TRAIL-induced apoptosis in DU145 prostate cancer cells (Fig. 
3.7). Taken together, our data indicate that the TRAIL-activated p38 MAPK 
pathway results in inhibition of TRAIL-induced apoptotic pathway by preventing 
MOMP. Since MOMP is highly controlled by BCL-2 family members, we 
speculated that p38 MAPKs might regulate BCL-2 family members and found 
that p38 MAPKs regulates transcription of MCL-1 (Fig. 3.9) and that MCL-1 is 
critical for mediating TRAIL resistance (Fig. 3.11; Fig. 3.12).  
Exposure to TRAIL alone led to robust DISC formation, caspase-8 
activation, and near complete BID cleavage, ruling out a prominent role for c-
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FLIP in mediating TRAIL resistance (Fig. 3.5; Fig. 3.8). Endogenous tBID, 
however, did not induce apoptosis unless MCL-1 expression levels were 
downregulated through simultaneous inhibition of the TRAIL-activated p38 
pathway, knockdown of MCL-1 by RNA interference, or antagonism of MCL-1 
by ectopically-expressed NOXA (Fig. 3.11; Fig. 3.12). The fact that ectopic 
overexpression of tBID could induce apoptosis, whereas NOXA could not, 
suggests that there was simply insufficient generation of endogenous tBID 
following TRAIL treatment to fully antagonize MCL-1 and/or directly activate 
BAK. Our data do not exclude either the direct or indirect activation models as 
previously posited, but it is worth noting that BIM (which like tBID is proposed 
to be a “direct activator”) has been shown to antagonize antiapoptotic BCL-2 
family members and directly activate BAX (Merino et al., 2009). 
An interesting observation we made while investigating the role of p38 
MAPKs in the regulation of MCL-1 was that low MCL-1 levels reduced by 
SB203580 treatment rebounded upon cotreatment with TRAIL. This observation 
led us to speculate that a secondary pathway must exist to upregulate the 
expression of MCL-1 following cotreatment with TRAIL plus SB203580.  
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Chapter 4.  TRAIL-induced MOMP activates a ROS-dependent                
JNK pathway that upregulates MCL-1 expression and partially rescues      
cells from apoptosis 
 
4.1  Introduction 
 MCL-1 is a highly expressed prosurvival protein in human malignancies and 
its cellular expression is tightly regulated via multiple mechanisms (Akgul, 2009). 
Regulation of MCL-1 expression occurs at multiple levels. Furthermore, it is 
rapidly downregulated during apoptosis, whereas its expression is induced by 
survival stimuli. Several kinases such as MAPKs, Janus kinases (JAKs), AKT, 
and glycogen synthase kinase (GSK)-3ß have been shown to phosphorylate MCL-
1 leading to regulation of MCL-1 expression at multiple levels (Akgul, 2009; 
Craig, 2002). The rapid and complex regulation allows MCL-1 to be adapted in 
response to rapidly changing conditions. 
 Reactive oxygen species (ROS) have been implicated in a wide variety of 
pathologies, including cancer, type II diabetes, arteriosclerosis, chronic 
inflammatory processes, ischemia/reperfusion injury, and various 
neurodegenerative diseases (Droge, 2002). The mitochondrial respiratory chain is 
the major source of intracellular ROS generation. Cellular metabolism depends on 
the continuous supply of ATP from the mitochondria. Thus, any damage that 
impairs the function of the respiratory chain might have an impact on cell 
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viability. To protect cells from oxidative insult, mitochondria contain an elaborate 
defense system to detoxify ROS and repair ROS-induced damage.  
 Oxidative stress is generally defined as an imbalance that favors the 
production of ROS over antioxidant defenses. About 1-2% of the molecular 
oxygen consumed during normal physiological respiration is converted into 
superoxide radicals. The one electron reduction of molecular oxygen produces a 
relatively stable intermediate, superoxide anion (O2·¯), which serves as the 
precursor of most ROS and the dismutation of superoxide anions by superoxide 
dismutases results in the production of hydrogen peroxide (H2O2).  Fe2+- (or 
Cu2+)-driven cleavage of H2O2 in a Fenton reaction can generate highly reactive 
hydroxyl radical (OH·) (Klaunig and Kamendulis, 2004). The mitochondrial 
electron transport chain contains several redox centers that leak electrons to 
molecular oxygen, serving as a primary source of superoxide production. O2·¯ 
production by complex I has been shown to be stimulated in the presence of 
succinate, a substrate of complex II (Liu et al., 2002) and is generated on the 
matrix side of IMM (de Vries, 1986). In addition to complex I, complex III is an 
important site of O2·¯ production (Grigolava et al., 1980), especially when 
mitochondrial respiration is suppressed by antimycin A, an inhibitor of complex 
III, O2·¯  produced at this site appears on both sides of the IMM (Muller et al., 
2004).  
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 ROS have been reported to affect the apoptotic process in the mitochondria. 
For instance, cytochrome c, one of the critical players within the electron 
transport chain, is normally bound to the IMM by an association with the anionic 
phospholipid cardiolipin. ROS facilitate the detachment of cytochrome c from 
cardiolipin via oxidation of cardiolipin, leading to a reduction in its affinity for 
cytochrome c. This results in an increase in the free pool of cytochrome c within 
the inner membrane space, which can in turn be released into the cytosol upon 
MOMP (Kagan et al., 2005). 
  In the present study, I have investigated the role of a secondary ROS-
dependent JNK pathway activated by MOMP in the regulation of MCL-1 
expression. 
 
4.2  Results 
As already noted, SB203580 inhibited TRAIL-activated p38 MAPKs, 
thereby preventing the expression of MCL-1 during the first 2-3 h following 
treatment with TRAIL and sensitized the cells to apoptosis (Fig. 3.1; Fig. 3.2; Fig. 
3.9C). MCL-1 expression levels, however, partially rebounded ≥4 h later, 
concomitant with caspase activation (Fig. 3.9C, D; data not shown). MCL-1 
expression levels are tightly regulated by phosphorylation from several kinases. 
Thus, we speculated that, in addition to transcriptional regulation of MCL-1 by 
p38 MAPKs, MCL-1 expression levels might also regulated by another pathway 
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Figure 4.1  JNKs activated by cotreatment with TRAIL plus SB203580 
partially protects cells from apoptosis.  
 
(A) DU145 cells were treated with TRAIL (500 ng/mL) ± SB203580 (50 μM) and 
immunoblotted for active p-JNK (Thr-183/Tyr-185), p-ERK (Thr-202/Tyr-204), 
and p-AKT (Ser-473). (B) Cells were treated with TRAIL ± SB203580 ± JIP 
peptide (10 μM) and the percentage of cell death was determined by Annexin 
V/PI staining and flow cytometry. Each bar represents the mean of three separate 
experiments ± SEM. Note, in the inset to panel B, the inhibitory effect of JIP was 
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Figure 4.2  TRAIL/SB20380-activated JNKs transcriptionally upregulate 
MCL-1 expression. 
 
(A) Cells were treated with TRAIL ± SB203580 ± JIP peptide (10 μM) and 
assayed for MCL-1 expression at the protein (immunoblotting) and (B) 
transcriptional (qRT-PCR) levels. Each bar represents the mean of three separate 




upon cotreatment with TRAIL plus SB203580. In order to characterize this 
resurgence in MCL-1 expression and to assess its potential impact on cell death, 
we treated cells with TRAIL ± SB203580 and once again assayed them for the 
activation of several kinases, including JNKs, ERKs, and AKT. Interestingly, 
ERKs were constitutively active, and there was no difference in AKT 
phosphorylation, whereas JNKs were robustly activated, but only in cells 
cotreated with TRAIL plus SB203580 (Fig. 4.1A, lane 4). More importantly, a 
cell-permeable peptide inhibitor of JNK, derived from JNK interaction protein 
(JIP), inhibited JNK activity (Fig. 4.1B, inset, lanes 3 and 4), prevented entirely 
the rebound in MCL-1 protein expression levels (Fig. 4.2A, lanes 6 and 8), and 
further sensitized cells to apoptosis (Fig. 4.1B; compare TRAIL+SB+JIP with 
TRAIL+SB, p<0.05). Consistent with the result shown in Fig. 4.2A, the rebound 
in MCL-1 mRNA levels were completely blocked in the presence of JIP.  
Since JNKs were activated relatively late following cotreatment with 
TRAIL plus SB203580, we questioned whether caspases might play a role in their 
activation, and indeed, addition of zVAD-fmk inhibited fully the activation of 
JNKs (Fig. 4.3A, lanes 6 and 8). Given that (i) caspase-dependent cleavage of 
BID and downregulation of MCL-1 was required to induce MOMP following 
exposure to TRAIL plus SB203580 (Fig. 3.8, 13), (ii) mitochondrial perturbation 
often leads to the production of ROS (Ricci et al., 2004), and (iii) ROS are 












Figure 4.3  JNK activation by TRAIL plus SB203580 is ROS dependent. 
 
(A) DU145 cells were treated with TRAIL ± SB203580 ± the ROS scavenger 
catalase (CAT; 100 U) or the polycaspase inhibitor zVAD-fmk (50 μM), and 
immunoblotted for MCL-1 expression, and (B) assayed for ROS production by 
flow cytometry using the fluorescent dye DCDFA. Each bar represents the mean 
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Figure 4.4  TRAIL-induced MOMP activates the ROS-dependent JNK 
pathway. 
 
(A) DU145 cells were treated with TRAIL ± SB203580 and assayed for ROS 
production by flow cytometry using pHyPer-Mito, a mitochondrial-localized 




inhibition of MKPs (Kamata et al., 2005; Tobiume et al., 2001), we further 
speculated that ROS might be responsible for the activation of JNKs in our 
studies. As predicted, TRAIL plus SB203580 induced a significant caspase-
dependent increase in the production of ROS, as determined by the oxidant-
sensitive fluorescent dye DCDFA (Fig. 4.3B), and addition of the ROS scavenger 
catalase prevented the activation of JNKs (Fig. 4.3A, lanes 6 and 7). DCDFA 
however is largely cytosolic, so to specifically invoke a role for mitochondria in 
the production of ROS, we transfected cells with a mitochondrial-localized 
circularly-permuted yellow fluorescent protein, inserted into the regulatory 
domain of the oxidant sensitive E. coli transcription factor OxyR (pHyPer-Mito) 
(Belousov et al., 2006). As shown in Fig. 4.4, control cells and those treated with 
SB203580 or TRAIL alone exhibited little activation of the pHyPer-Mito probe. 
In stark contrast, cells cotreated with TRAIL plus SB203580 — a combination 
that induced MOMP, cytochrome c release, and a loss in Δψm (Fig. 3.6) — 
displayed a profound increase in mitochondrial fluorescence (Fig. 4.4A, B). 
Taken together, the data supported a model wherein TRAIL plus SB203580 
induced BID activation and downregulation of MCL-1, resulting in MOMP, 
cytochrome c release, a loss in Δψm, increased ROS production, activation of 
JNKs, and ultimately, a resurgence in the expression of MCL-1 (Fig. 4.5). Thus, 
even during times of profound stress, e.g. following MOMP, the affected cells 





Figure 4.5 Model of TRAIL-activated proapoptotic and antiapoptotic 
pathways. 
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reemphasizing the importance of MCL-1 as a regulator of TRAIL-induced cell 
death. 
 
4.3  Discussion 
 MCL-1 has been shown to mediate TRAIL resistance in human cancer cells 
(Han et al., 2006; Meng et al., 2007; Ricci et al., 2007) and consistent with 
previous studies, our studies in prostate cancer cells reveal the critical importance 
in maintaining MCL-1 expression levels in order to suppress TRAIL-induced 
apoptosis. Indeed, even following MOMP, mitochondrial-generated ROS 
stimulated a secondary JNK pathway that transcriptionally upregulated the 
expression of MCL-1 and partially rescued some cells from death (Fig. 4.1-4. 4).  
 The mitochondrial-generated ROS were most likely produced at complex III, 
due to inefficient electron transfer following the release of cytochrome c, or 
alternatively at complex I, due to caspase-dependent cleavage of NDUFS1 (Fig. 
4.5) (Ricci et al., 2004). Irrespective, these results are in stark contrast to TNF 
signaling, wherein ROS are produced by NADPH oxidases upstream of 
mitochondria and in turn activate ASK1 or inactivate MKPs, resulting in 
prolonged JNK activation, MOMP, and apoptosis (Kamata et al., 2005; Kim et al., 
2007; Tobiume et al., 2001). Our results show that p38 MAPK regulates the 
transcription of MCL-1 (Fig. 3.9) and that JNK also appears to control MCL-1 
expression levels via transcription following cotreatment with TRAIL plus 
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SB203580 (Fig. 4.2). However, at this stage, the transcription factor(s) 
responsible for p38 MAPK and JNK-dependent upregulation of MCL-1, 
following treatment with TRAIL and TRAIL+SB203580, respectively, remain 
unknown and are currently under investigation. STAT3 and PU.1 have previously 
been implicated in MCL-1 expression; however, PU.1 is generally restricted to 
hematopoietic tissues, and dominant-negative mutants of STAT1, STAT3, and 
ATF2 (a p38α and JNK-targeted transcription factor) failed to potentiate TRAIL-
induced apoptosis (data not shown). 
 Our data propose a model wherein TRAIL stimulates its receptors, TRAIL-
R1 and/or TRAIL-R2, resulting in recruitment of the adapter protein FADD and 
activation of procaspase-8 within the DISC. Caspase-8 subsequently processes 
procaspase-3, but active caspase-3 is rapidly inhibited by IAPs, including XIAP. 
Caspase-8 also cleaves and activates BID, and tBID would normally induce BAK-
dependent MOMP and release the IAP antagonist Smac/DIABLO. However, 
TRAIL receptor stimulation simultaneously activates an antiapoptotic TAK1 → 
MKK3/MKK6 → p38 MAPK signaling pathway that transcriptionally 
upregulates MCL-1, which in turn sequesters/neutralizes tBID. Disruption of this 
signaling pathway at any step sensitizes cells to TRAIL, but remarkably, even 
following MOMP, mitochondrial-generated ROS activate a secondary JNK 
pathway that similarly leads to transcriptional upregulation of MCL-1 and partial 
protection from cell death (Fig. 4.5). 
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Chapter 5. Concluding remarks 
 
 Apoptosis is a tightly controlled physiological process of cell elimination 
that plays a critical role in development and homeostasis (Kerr et al., 1972). It is 
important for maintaining appropriate cell numbers in tissues, serving as a balance 
to cell proliferation. Thus, deregulated apoptosis has been implicated in a variety 
of diseases. Too much apoptosis results in cell-loss disorders, whereas too little 
apoptosis can prevent tumor cells from dying, leading to cancer (Fadeel et al., 
1999b). Cancer is a leading cause of premature human death and commands 
considerable research attention. However, despite significant progress in the 
treatment of cancer over the past four decades, the prognosis for many cancers 
remains poor. Inherent and acquired resistance of tumor cells to existing 
chemotherapeutics is one of the principal reasons for this and highlights the 
importance of devising novel therapeutic approaches.  
 Multicellular organisms normally eliminate damaged cells most effectively 
through apoptosis, resulting in death. However, one of the hallmarks of cancer 
cells is active avoidance of apoptosis, thereby promoting their survival. 
Consequently, methods of inducing apoptosis have become an important approach 
in the design of new cancer therapies. Many proapoptotic agents have been 
developed, but their unacceptable toxicity to normal tissues usually limits their 
use in the clinic.  
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 TRAIL, as one of the TNF family members, induces apoptosis through 
engagement of death receptors. It has generated tremendous enthusiasm as a 
potential tumor-specific cancer therapeutics, because as a stable trimer, it 
selectively induces apoptosis in many transformed cells, but not in most normal 
cells (Falschlehner et al., 2009). Early-phase clinical trials have been initiated in 
cancer patients, testing for safety, pharmacokinetics, and preliminary evidence of 
anti-tumor activity. Recombinant TRAIL (Genentech and Amgen), and 
monoclonal antibodies targeting TRAIL-R1, such as mapatumumab (HGS-ERT1; 
Human Genome Sciences), and TRAIL-R2, such as lexatumumab (HGS-ERT2; 
Human Genome Sciences), AMG 655 (Amgen) and apomab (Genetech) have 
been developed and are being tested in human clinical trials.  
 However, many primary tumors are inherently resistant to TRAIL-induced 
apoptosis and require additional sensitization. Therefore, understanding the 
mechanisms of TRAIL resistance and developing strategies to overcome that 
resistance is critical for future success. Many studies over the last decade have 
proposed mechanisms responsible for TRAIL resistance. However, these 
mechanisms may differ depending upon the cell-type, etc. Herein, we have 
demonstrated that TRAIL activates a TAK1 → MKK3/MKK6 → p38 pathway in 
prostate cancer cells that transcriptionally upregulates expression of the 
antiapoptotic BCL-2 family member MCL-1, resulting in TRAIL resistance. 
TRAIL triggers a prodeath TRAIL-R1/TRAIL-R2 → FADD → caspase-8 
 90 
pathway; however, the activity of caspase-3 is largely blocked by IAPs, such as 
XIAP. Therefore, disruption of the p38 MAPK pathway is required to suppress 
MCL-1 expression, thereby allowing tBID to activate the proapoptotic BCL-2 
family member BAK and stimulate MOMP. This results in release of the IAP 
antagonist Smac/DIABLO, which relieves the inhibition of caspase-3 by XIAP, 
leading to apoptosis. 
 Although MCL-1 is an antiapoptotic BCL-2 family protein that plays 
essential roles in the development and differentiation of normal cells, deregulation 
of MCL-1 contributes to human malignancies. Overexpression of MCL-1 has 
been shown in a variety of human hematopoietic, lymphoid cancers and solid 
tumors (Aichberger et al., 2005; Derenne et al., 2002; Sieghart et al., 2006), and 
also appears to be a key factor in the resistance of some cancer types to 
conventional cancer therapies (Hussain et al., 2007; Nguyen et al., 2007; Paoluzzi 
et al., 2008). In particular, MCL-1 has been reported to mediate TRAIL resistance 
in various cancer cells. Downregulation of MCL-1 by siRNA enhances TRAIL-
induced apoptosis in cancers (Han et al., 2006; Meng et al., 2007; Wirth et al., 
2005), and overexpression of  mir-29b, which inhibits translation of MCL-1, 
makes cancer cells sensitive to TRAIL-induced apoptosis (Mott et al., 2007). 
MCL-1 expression is induced by TRAIL in TRAIL-resistant cells through an NF-
κB-dependent pathway and disruption of TRAIL-induced MCL-1 sensitizes cells 
to apoptosis (Ricci et al., 2007). Consistent with previous studies, we have found 
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that TRAIL-induced MCL-1 is a critical factor for TRAIL resistance in human 
prostate cancer cells, not through NF-κB but rather through a p38 MAPK pathway. 
We did investigate the role of NF-κB in TRAIL resistance in DU145 cells and 
found that NF-κB was constitutively active. However, inhibition of NF-κB had no 
effect on TRAIL-induced cell death (data not shown). MCL-1 has also been 
shown to be regulated by several additional kinase-activated transcription factors 
(Epling-Burnette et al., 2001; Nijhawan et al., 2003; Puthier et al., 1999; Wang et 
al., 1999), and our results have shown that both p38 MAPK and JNK regulate the 
transcription of MCL-1, although it remains unclear which transcription factors 
are targeted. Nevertheless, we have shown for the first time that MCl-1 is 
transcriptionally regulated following TRAIL treatment, thereby leading to 
resistance.  
 Finally, there are several clinical implications that have arisen from our 
studies, particularly related to the use of small molecule BCL-2 antagonists and 
Smac mimetics. There is currently legitimate excitement surrounding the use of 
BCL-2 antagonists, such as ABT-737, in the treatment of tumors made resistant to 
conventional chemotherapy through overexpression of antiapoptotic BCL-2 
family members. Similar to BAD, however, ABT-737 selectively targets BCL-2, 
BCL-XL, and BCL-W, but not MCL-1, and thus is unlikely to synergize with 
TRAIL in the treatment of MCL-1 overexpressing tumors. One potential approach 
for bypassing the antiapoptotic BCL-2 family members altogether could be to 
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utilize Smac mimetics, which antagonize IAPs and liberate active caspases-3 and 
-7 following their initial processing by caspase-8. Indeed, consistent with previous 
studies in other cancer cell types, from our laboratory and others, we found that 
release of Smac (rather than cytochrome c) was essential for TRAIL-induced 
apoptosis in DU145 prostate cancer cells (Fig. 3.7). Smac mimetics however 
reportedly induce apoptosis by stimulating autoubiquitination and degradation of 
cIAP1 and cIAP2, resulting in activation of the noncanonical NF-κB pathway and 
upregulation of TNF. Consequently, it remains unclear how effective these agents 
will be in vivo or whether they will exhibit significant side effects due to the 
production of TNF. Our studies suggest that TRAIL might instead be used 
effectively in combination with clinically available p38 MAPK inhibitors for the 
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